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“I pictured myself lying on a huge wave on a stormy sea and just went with the flow”  







Background: Patients with breast cancer undergoing neoadjuvant chemotherapy are often treated 
as outpatients and experience several distressing symptoms and concerns over a long period, which 
must be managed at home. Routine use of patient reported outcomes facilitates communication with 
the healthcare of what needs the patient may have. To support patients with cancer during treatment, 
the use of mHealth has shown promising results in reducing symptoms and improving quality of 
life. 
Aim: To evaluate how an interactive app for reporting and managing symptoms provides supportive 
care in patients with breast cancer during neoadjuvant chemotherapy.  
Methods: Through the app patients report symptoms daily as well as write free text messages. The 
reports are monitored and responded to by a contact nurse at the clinic. Further, the patients have 
access to self-care advice and can view their reported symptoms in graphs. This randomized 
controlled trial was conducted according to the Medical Research Council’s framework for complex 
interventions. In Study I, the patients were randomized to an intervention group (n = 74), who used 
the app during treatment in combination with standard care, and to a control group (n = 75), who 
received standard care alone. Both groups answered questionnaires regarding symptoms and health-
related quality of life before start of treatment and two weeks after end of treatment, to evaluate if 
the intervention had any effects on the patients’ symptoms and health-related quality of life.    
Study II investigated the patients’ engagement in using the app. Logged data from the patient’s app 
usage (n = 74) and predictors of usage were analyzed. Telephone interviews were conducted with 
the patients about how they perceived using the app during treatment. In Study III, face-to-face 
interviews were conducted three months after end of neoadjuvant chemotherapy with patients from 
both groups (n = 40) about perceptions of care during treatment with or without using the app. 
Results: In Study I, patients who used the app during treatment perceived less prevalence of 
symptoms and symptom distress and better emotional functioning two weeks after end of treatment 
compared with the patients in the control group. In Study II, the adherence to reporting in the app 
was 83%. The components included in the app, such as self-care advice and graphs, were used by 
most of the patients. Higher age predicted fewer free text messages sent. The app was considered 
easy to use with a relevant content, which facilitated support for symptom management and own 
monitoring of symptoms as well as having a close, continuous, and interactive contact with the 
contact nurse. In Study III, results showed that most of the patients, whether they had used the app 
or not, were satisfied with the care during the treatment. The patients who had used the app 
perceived it as an added value for support as they were provided easy access to information and 
communication regarding experienced symptoms with the contact nurse. Moreover, Interaktor 
facilitated performing self-care by using the self-care advice and promoted own participation in 
care. 
Conclusions: This thesis shows that patients with breast cancer can receive supportive care by 
using an app such as Interaktor during neoadjuvant chemotherapy. By facilitating interaction and 
communication with the contact nurse, symptoms can be identified and managed in a timely manner 
as well as enhancing patients’ participation in their own care. 
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During my clinical nursing career, I have primarily worked as an oncology nurse with 
patients with breast cancer at the outpatient department at Karolinska University Hospital 
(formerly Radiumhemmet). Since the department is research intense, I had the privilege of 
continuously working together with researchers in both oncology nursing and breast cancer 
oncology, which has inspired me and laid the foundation for my interest in research. The 
advances in new treatments have led to increased survival. However, this also means 
symptoms and concerns for the patients who receive it, which needs to be managed over a 
long period of time.  
In my experiences working as a contact nurse, patients with breast cancer have different 
needs for support during their treatment and they want to be involved in the care in some 
way. Information and management of symptoms, as well as having regular contact with and 
easy access to a contact nurse when needed, is support that seems meaningful for the 
patients to be able to cope with their disease and treatment. To deliver this support nurses 
play an important role by using various nursing interventions. 
When I was told that the Doctoral School in Health Care Sciences at Karolinska Institutet 
announced for a doctoral student in a research project focusing on how patients with breast 
cancer can be supported by using an interactive app in clinical nursing care, I immediately 
thought that this was the natural step for me to take to gain in-depth understanding and 
knowledge of how such intervention can be supportive for the patients. 
My hope is that the findings in this thesis will contribute to knowledge of how patients with 
breast cancer undergoing neoadjuvant chemotherapy perceive their situation and care and 
how they can be supported by making care accessible and communicative as well as 






2.1 Breast cancer 
In Sweden, breast cancer is the most common cancer among women. In 2018, over 7800 
women and just over 60 men were diagnosed. The same year around 1500 individuals died 
because of the disease (The National Board of Health and Welfare & The Swedish Cancer 
Society, 2018). The median age for getting the disease is 64 years and fewer than five 
percent are under 40 years old (The Swedish Cancer Society, 2020). Over the years there 
has been an increase in the number of individuals who are diagnosed with breast cancer and 
a decrease in mortality (The National Board of Health and Welfare & The Swedish Cancer 
Society, 2018). This can be explained by early detection of the disease through public 
mammography screening programs as well as advances in treatments (Cardoso et al., 2019; 
Nordenskjöld et al., 2018). 
2.1.1 Treatment methods for breast cancer 
There are several approaches to treating breast cancer. Surgery is commonly performed either 
before or after different medical treatments. The surgical techniques have evolved aiming to 
be effective in removing the tumor, but also to improve the cosmetic result and longtime 
functions (Waks & Winer, 2019). The surgical techniques for breast cancer commonly 
consist of breast-conserving surgery or mastectomy, which can be combined with 
reconstruction of the breast (Zurrida & Veronesi, 2015). Breast-conserving surgery aims to 
remove the tumor with tumor free margins around the tumor, but not the breast itself, while 
mastectomy removes the tumor as well as the breast. Tumor characteristics, the patient’s age, 
volume of the breast, further oncological treatment, and patient’s wishes are some examples 
of factors that determine which surgical technique should be performed. It has been 
concluded that besides preventing locoregional recurrence and improving survival, the 
surgical treatment of breast cancer also focuses on the patients’ quality of life and body image 
(Riis, 2020). During the surgery, a standard procedure is also the sentinel-node biopsy, where 
a radioactive isotope and blue dye is injected close to the tumor. By doing this, the first 
lymph node that drains the tumor is identified and examined. If there is no sign of metastasis, 
an axillary dissection is avoided. This technique not only predicts the status over the entire 
axilla, it can also prevent the patient from being affected by lymphedema, pain and mobility 
impairment of the arm, which an axillary dissection may cause (Confederation of Regional 
Cancer Centres in Sweden, 2020b; Zurrida & Veronesi, 2015). Medical treatments can 
consist of chemotherapy, which can be combined with targeted drugs (anti-HER2 
treatments), and anti-hormonal treatment (endocrine therapy). Radiation therapy is also 
frequently used after surgery and chemotherapy to eliminate any remaining cancer cells 
(Confederation of Regional Cancer Centres in Sweden, 2020b). The decision about which 
treatment should be given is based on several factors such as characteristics of the tumor, 
such as tumor type, grade, stage of the disease (Elston-Ellis), proliferation rate (Ki-67), 
hormonal-receptors status (estrogen = ER and progesterone = PR) and HER2 status (human 




affect the decision of treatment (Bourdeanu & Liu, 2015; Colomer et al., 2019; Confederation 
of Regional Cancer Centres in Sweden, 2020b; Gamucci et al., 2018; Klein et al., 2019). 
2.1.2 Chemotherapy 
Chemotherapy is a systemic treatment method, where the goal is to destroy cancer cells and 
stop them from dividing uncontrollably. The treatment is given with different intentions 
such as curative, which aims to eliminate all cancer cells in the body, as adjuvant, where the 
goal is to eliminate cancer cells that might be left after surgery, or as neoadjuvant before 
surgery to shrink the tumor. Chemotherapy given as palliative treatment can help to slow 
down or stop the progress of the cancer temporarily or relieve symptoms (Fisusi & Akala, 
2019; Nilbert, 2013; Schmidt, 2014). 
Chemotherapy is given in cycles. The number of cycles and how long the intervals are 
between them, depends on how long the effect of the chemotherapy lasts, recovery time for 
the patient and the overall length of the treatment. Common cycles are weekly treatment, 
every other week or every third week, which means that the total length of the treatment 
can vary between 12 and 18 weeks. Further, the treatment can be given as single-agent, 
meaning that only one drug is given, or as multi-agents, where a number of drugs are 
combined (Chatterjee & Erban, 2017; Colomer et al., 2019; Gianni et al., 2012). This means 
that there can be many different combinations depending on how the agents work to have 
effect on the tumor (Waks & Winer, 2019). In Sweden, patients are treated according to 
recommendations written in the national care guidelines for breast cancer (Confederation of 
Regional Cancer Centres in Sweden, 2020b). The decisions on which chemotherapy agents 
should be given, dosages, in which order and cycles are based on results from several 
clinical trials conducted over the years (Waks & Winer, 2019). Clinical trials are also 
continuously ongoing to develop and evaluate new treatments. In Sweden, PREDIX II Her 
2 and NordicTrip are neoadjuvant clinical trials, where tumor characteristics play a crucial 
role such as HER2 status or triple negative breast cancer meaning that the tumor is tested 
negative for hormonal receptors and HER2 (Confederation of Regional Cancer Centres in 
Sweden, 2020a). Studies based on tumor characteristics as well as individual factors for 
each patient will hopefully result in knowledge about which treatments will be most 
beneficial for the individual patient (Falzone et al., 2018). 
2.1.3 Undergoing treatment with neoadjuvant chemotherapy 
Historically, neoadjuvant chemotherapy (NACT) was introduced in the 1970s (Early Breast 
Cancer Trialists’ Collaborative Group, 2018). This was based on studies with positive 
results in patients with inoperable tumors who had received NACT before surgery to 
decrease the size of the tumor to be operable (Mieog et al., 2007). Today, NACT is an 
established and commonly used treatment in early-stage and locally advanced breast cancer 
(tumor size from 20 mm to 50 mm or spread to axillary lymph nodes), as well as 
inflammatory and primarily non-operable breast cancer (Heil et al., 2020; Mrkonjic et al., 




receiving NACT often have more aggressive characteristics of the tumor (Cain et al., 2017; 
Graham et al., 2015; Haddad & Goetz, 2015). 
In Sweden, the proportion of patients receiving NACT has doubled from nine percent in 
2009 to 18 percent in 2018 (Regional Cancer Center Stockholm-Gotland, 2020). The 
chemotherapy agents given as NACT are predominantly the same as those given as 
adjuvant (Early Breast Cancer Trialists’ Collaborative Group, 2018; Waks & Winer, 2019). 
Combinations of Anthracyclines, Alkylators, Antimetabolites and Taxanes are commonly 
given as NACT followed by Taxanes as a single-agent treatment (Confederation of 
Regional Cancer Centres in Sweden, 2020b). If the tumor has shown to be HER2 positive, 
anti-HER2 drugs such as Trastuzumab and Pertuzumab is added to the treatment 
(Chatterjee & Erban, 2017; Colomer et al., 2019; Gianni et al., 2012). In recent years, 
interest in adding immunotherapy to chemotherapy has risen even in the neoadjuvant 
setting after showing positive results in treatment of metastatic breast cancer (Adams et al., 
2019; Schmid et al., 2020). Immunotherapy uses components of the patient’s own immune 
system to detect and destroy cancer cells (Koury et al., 2018). If a patient responds well to 
NACT, the prognosis of survival increases (Klein et al., 2019; Li et al., 2019; Romero et al., 
2013). Clinical trials using immunotherapy aim to investigate whether the prognosis can 
improve even further (Garcia-Aranda et al., 2019; Mina et al., 2019). 
Neoadjuvant chemotherapy is considered both effective and safe. Besides the benefit of 
reducing tumor size to facilitate breast conserving surgery rather than mastectomy, which 
can decrease morbidity associated with axillary surgery, NACT allows to treat possible 
micro metastases early and provides valuable prognostic information (Cain et al., 2017; 
Caparica et al., 2019; Curigliano et al., 2017; Haddad & Goetz, 2015). When NACT is 
completed, the patient undergoes surgery to remove the primary tumor. A decision on 
whether further treatment is warranted is also taken for example more chemotherapy, 
radiation therapy and/or anti-hormonal therapy (Bourdeanu & Liu, 2015). 
Despite the benefits, chemotherapy is associated with treatment-related side-effects causing 
several distressing symptoms and concerns (Bergh et al., 2001; Fisusi & Akala, 2019; 
Pondé et al., 2019). Chemotherapy does not have the ability to distinguish between cancer 
cells and normal cells. Cancer cells grow fast like many of the normal cells in the body 
such as in the blood and hair, but also cells in the mouth and gastrointestinal tract. When 
chemotherapy is given, the normal cells are also affected which cause symptoms (Nilbert, 
2013). Depending on which chemotherapy agents are used, dosages, number of treatment 
cycles, individual factors such as age and comorbidity as well as coping strategies and 
social support, the patients experience of prevalence, frequency and severity of symptoms 
can vary (Gibbons & Groarke, 2018; Lai et al., 2017; Miaskowski et al., 2014). Some 
patients complete the treatment smoothly and can live a relatively normal life during 
treatment while others experience many symptoms and concerns, which causes great 
suffering (Lai et al., 2017). Frequently patients express having multiple symptoms 




Tiezzi et al., 2017), commonly between 10 to 32 symptoms (Miaskowski et al., 2014; 
Ward-Sullivan et al., 2017), which can be associated with both the treatment and the illness 
itself (Bower, 2008; Davis & Kirkova, 2008; Galipeau et al., 2019; Kirca & Kutlutürkan, 
2018; McFarland et al., 2018; Miaskowski et al., 2017; Pearce et al., 2017) (Table 1). These 
symptoms and concerns affect the patient’s physical, psychological, and social well-being 
and subsequently have a negative impact on quality of life (Avis et al., 2017; de Ligt et al., 
2019; Karimi & Brazier, 2016; Tang et al., 2018).  
 
 





• Breathing difficulties 
• Changes in taste and smell 






• Hair loss 
 




• Numbness or tingling in hands and feet 
• Oral mucositis 
• Pain 
• Sadness 




Note. The symptoms and concerns presented in Table 1 are from Bower (2008); Davis and Kirkova 
(2008); Galipeau et al. (2019); Kirca & Kutlutürkan (2018); McFarland et al. (2018); Miaskowski et 
al. (2017) and Pearce et al. (2017). 
 
Even though perception of symptoms during chemotherapy for breast cancer is well known, 
how patients perceive symptoms and quality of life during NACT has not been studied to 
the same extent (Beaver et al., 2016; LeVasseur et al., 2020). The symptoms perceived 
associated with NACT may not differ that much since the chemotherapy agents given are 
the same as for adjuvant treatment. To be considered though is that patients planned for 
NACT are relatively young and may have to balance own needs against their families, 
manage financial difficulties and maintain their careers (Adams, 2010; Beaver et al., 2016; 
Hamer et al., 2017). The chemotherapy treatment often starts quickly after diagnosis, and 
the patients must cope with a rapid transition from being well to feeling ill while also 
dealing with the shock of the cancer diagnosis. Another stressful factor when undergoing 
NACT is the knowledge that the cancer is remaining in their body during the treatment 
(Beaver et al., 2016). 
 
2.2 Supportive cancer care 
In cancer care, supportive care is a concept that is frequently used, however there is no 
consensus over what it really entails (Cramp & Bennett, 2013; Hui, 2014). Often supportive 
care is used interchangeably with palliative care or hospice care (Hui, 2014). Also 




and survivorship (Multinational Association of Supportive Care in Cancer [MASCC], 
2020). All interpretations of supportive care have similarities such as multi-professional 
care for the patient, but there are large differences in how the services are performed and 
the patient population that receive it (Hui et al., 2013). In the early 1990s, the Supportive 
Care Framework for Cancer Care was developed by Fitch (2008), as a tool for healthcare 
professionals to define what type of help patients with cancer might require and how 
delivery of services should be approached and assessed according to patients’ individual 
needs, response to the situation, coping and adaption (Fitch, 2008). The supportive care 
needs differ from patient to patient depending on factors such as age, stage of disease, 
social and cultural context, and individual perceptions, as well as change over time, but 
regardless of what, the needs must be handled appropriately and timely (Loibl & Lederer, 
2014). The goal is to provide the best possible care which is accessible for all patients. 
Being diagnosed with breast cancer is often described as a shocking and overwhelming 
experience turning everyday life upside down, and as the forthcoming treatment begins, it 
affects the patients in several ways (Curtis et al., 2014; Landmark & Wahl, 2002). It has 
been concluded that patients have unmet supportive care needs during their treatment 
(Cardoso et al., 2013; Schmid-Büchi et al., 2013), which can be described as the difference 
between a patients perceptions of the support and the actual support that is required or 
desired (Hubbard et al., 2015) as well as possibly not receiving supportive care that is 
adequate (Cardoso et al., 2013; Schmid-Büchi et al., 2013). Patients with breast cancer 
often describe supportive care needs concerning how to cope with the disease, such as 
psychological and practical support and information about the treatment and the disease, 
related symptoms and how they can be managed (Fiszer et al., 2014; Loibl & Lederer, 
2014). The patients may perceive impaired well-being and quality of life if symptoms are 
uncontrolled and there is also a risk of poor treatment outcomes due to delay, dose 
reduction or if the treatment needs to be cancelled. Moreover, patients may need distressing 
visits to the emergency department or need care that requires hospitalizations (Lai et al., 
2017; McKenzie et al., 2011; Tang et al., 2018; Wyatt et al., 2015). Therefore, prevention 
and management of symptoms related to the cancer and its treatment constitutes a large part 
of supportive care in patients with cancer. The management includes both physical and 
psychological symptoms perceived by patients from diagnosis through treatment to post-
treatment care (Loibl & Lederer, 2014). According to The Symptom Management Model 
developed by Dodd et al. (2001), symptoms can be effectively managed if they are assessed 
based on severity, cause, and treatability. 
2.2.1 Perspectives on supportive care  
Within nursing, health is considered as a key concept (Wärnå-Furu, 2017) and closely 
related to the concept of a human being. The human being is viewed as one unit where 
physical, psychological, existential, and social dimensions interact with each other 
(Lindwall, 2017). When a human being becomes a recipient of care he or she is commonly 




human being, which means that perceptions of health are subjective, have different 
meanings for different patients and can change their character over time. Moreover, health 
and illness do not have to be opposites. Even though a patient has an illness, the patient can 
perceive health (Ekebergh, 2015). Therefore, it might be conflicting that in nursing 
literature how patients with breast cancer perceive their situation and treatment is 
commonly described from the perspective of illness. An explanation is that reflections on 
their own health are usually not made when feeling well, but when they are affected by 
illness, the awareness of their own health increases, as the illness may interfere with daily 
life (Ekebergh, 2015). Due to illness, unmet needs, inability to take care of oneself and 
difficulties in adapting to the new situation are perceptions that often occur among patients 
(Meleis, 2011). 
Patients with breast cancer describe that to feel supported during treatment, they request 
communication and interaction with healthcare professionals, easy access to the care as 
well as information and help to manage symptoms related to the treatment (Droog et al., 
2014). Since perceptions of being diagnosed with breast cancer and the forthcoming 
chemotherapy are highly subjective as well as entailing a prolonged and complex care, it is 
crucial that the patients are provided with appropriate supportive care that each patient 
requests and needs (Brédart et al., 2013). There are nurse-led interventions conducted to 
support patients with breast cancer (Chan et al., 2020; Charalambous et al., 2018; 
Tuominen et al., 2019). The majority of the interventions are randomized controlled trials 
(RCTs) or controlled before and after studies. Commonly they involved teaching or 
provision of information and nurse-led follow up by assessing and monitoring symptoms 
and providing advice for those symptoms and subsequently reporting back to the physician. 
Primarily, the interventions were delivered face-to-face, over the telephone or online (Chan 
et al., 2020; Charalambous et al., 2018; Tuominen et al., 2019). Among the interventions 
described by Chan et al. (2020), Charalambous et al. (2018) and Tuominen et al. (2019), 
teaching or provision of information and nurse-led follow up during treatment were 
interventions that showed statistically significant positive effects on health-related quality 
of life and symptom burden. However, many had small sample sizes, inappropriate study 
designs, insufficiently described methods, and poorly reported results sections, making it 
hard to make interpretations and recommendations. It is therefore concluded that more 
research is needed to gain better insights into which interventions are effective and can then 
be further evaluated (Chan et al., 2020; Charalambous et al., 2018; Tuominen et al., 2019). 
To be considered is that, as most of the patients with breast cancer receive their treatment as 
outpatients, they are required to manage their situation at home over a long time period (Lai 
et al., 2017; McKenzie et al., 2011). Enhancing self-care is one nursing intervention that is 
of special importance in those patients (Coolbrandt et al., 2018; McCorkle et al., 2011). 
Studies have shown that performing self-care during treatment for cancer has several 
advantages. It can relieve symptoms, improve quality of life, help patients cope with the 
treatment as well as being advantageous for compliance with further treatments (Davis et 




et al., 2016). This can in the long run help patients achieve a faster return to daily activities 
and work (Pryce et al., 2007). Moreover, performing self-care can enhance interaction and 
communication with healthcare professionals, and by letting the patients take their own 
actions in managing symptoms related to treatment, patient participation can be achieved 
(Howell et al., 2017). 
The concept of patient participation is not well defined and various terms such as patient 
collaboration, patient involvement, partnership and patient empowerment are used 
interchangeably. Patient participation is often associated with decision making and does not 
always include the various aspects in which the patient can participate in healthcare 
(Longtin et al., 2010). In this thesis, patient participation focuses on the individual patient 
receiving nursing care, the collaborative relation between the patient and the contact nurse, 
shared information and knowledge, and active engagement in their own care (Angel & 
Frederiksen, 2015; Sahlsten et al., 2008). 
Even if the nurse has the responsibility to support the patients during treatment, the patients 
are also expected to participate in their own care (Tinetti & Basch et al, 2013), such as 
making decisions or expressing opinions about their treatment, sharing information with the 
healthcare professionals, asking questions and managing their own health (Longtin et al., 
2010; Vahdat et al., 2014). However, it is crucial to remember that patients might have 
different needs for participation (Frank et al., 2009). Some want to participate, and some 
want to stay passive (Cohen & Botti, 2015; Ringdahl et al., 2017). Patient participation 
should therefore be considered on an individual basis depending on the patients’ needs, 
wishes and situation (Angel & Frederiksen, 2015; Engqvist Boman et al., 2018). By taking 
each patient’s needs for participation into consideration and where there is collaboration 
and mutual communication between the patient and healthcare professionals, the supportive 
care becomes person-centered (Jordan et al., 2018; Santana et al., 2018). This means that 
the focus is on the patient behind the disease, rather than solely on the disease (Kaasa et al., 
2018). 
2.2.2 Patient-reported outcomes – subjective symptom reporting 
Patients’ perceptions of symptoms related to chemotherapy are as described highly 
subjective and can only be recognized by the patient without interpretation by the 
healthcare professionals (Dodd et al., 2001; Rhodes & Watson, 1987). The symptoms can 
be perceived in several dimensions such as prevalence, frequency, severity, bother, 
intensity, and distress (Henoch et al., 2018). Using patient-reported outcomes (PROs) is a 
strategy to gain a holistic view of the patients perceived symptoms. Patient reported 
outcomes can include symptoms, a patients physical, psychological, social and emotional 
functioning, and other reports concerning the patients’ health (U.S. Department of Health 
and Human Services FDA, 2006). The use of PROs has increased in cancer care (Howell et 
al., 2015). To measure PROs, instruments called patient-reported outcome measures 




Evidence has shown that routine use of PROMs by patients to report their symptoms and 
concerns can facilitate early detection of symptoms and impact of treatment, improve 
communication between patients and healthcare professionals, addressing the patients’ 
needs, and improve patient satisfaction (Berry, 2011; Berry, Blumenstein, et al., 2011; 
Kotronoulas et al., 2014; Maher, 2013; Snyder et al., 2014; Valderas et al., 2008) and 
participation in care (Chen et al., 2013; Howell et al., 2020). When used in clinical practice 
it is important that the questions used for assessment are tailored and relevant for the 
context in which they are used (Snyder et al., 2014). Since patients with breast cancer 
undergoing chemotherapy perceive various symptoms to various degrees, measuring PROs 
can better identify those patients who would benefit from actions taken with additional 
supportive care (Davis et al., 2018). 
2.2.3 mHealth – a digital solution 
Today digital health solutions within eHealth and mHealth are commonly used in cancer 
care (Charalambous, 2019). eHealth is a broader concept and involves internet and related 
technologies for delivering and enhancing health services and information (Eysenbach et 
al., 2001). eHealth has also been described as using digital tools to exchange information 
digitally to achieve and maintain health (Hofflander, 2020). Mobile technology, which 
refers to devices such as smartphones and tablets where various applications (apps) can be 
downloaded, have become a large part of people’s daily lives (Jeon & Park, 2015). This 
development has led to an increased use of mobile technology within healthcare called 
mHealth (Blake, 2013; Park, 2016). mHealth has been defined as “medical and public 
health practice supported by mobile devices, such as mobile phones, patient monitoring 
devices, personal digital assistants (PDAs), and other wireless devices” (World Health 
Organization [WHO], 2011). There are several reasons why the use of mHealth in 
healthcare has increased. The smartphones or tablets have powerful technical capabilities, 
people are attached to their phones and carry them everywhere (Klasnja & Pratt, 2012). 
Smartphones can also be used in large samples, accessing hard-to-reach groups and have 
the potential to be cost effective (Blake, 2008). 
Due to the rapid development within mHealth it is today possible to integrate and collect 
PROs in such devices instead of using paper-based questionnaires (Kaasa et al., 2018), 
which can decrease the risk of missing data, recall bias and transcription errors (Benze et 
al., 2019). Further, using digital solutions such as mHealth for reporting PROs in real time 
gives an opportunity to address and monitor patients’ unmet needs as well as support 
patients in management of symptoms through self-care advice. Moreover, mHealth helps 
increase communication between the patients and healthcare professionals and provides 
information about the treatment and related symptoms (Aapro et al., 2020; Kruse & Beane, 
2018; Richards et al., 2018; Rowland et al., 2020). 
There is increasing evidence showing that the patients with cancer using digital health such 
as mHealth are supported in various ways. Patients often appreciate to report symptoms to 




systems as usable, acceptable, and feasible (Heynsbergh et al., 2019; Moradian et al., 
2018). These systems offer patients to interact with the healthcare professionals by regular 
self-reporting and monitoring of symptoms during treatment. Further, alerts are sent to the 
healthcare professionals according to predefined levels, which the healthcare professionals 
responds to by contacting the patient (Basch et al., 2007; Denis et al., 2014; Drott et al., 
2016; McCann et al., 2009; Weaver et al., 2014). mHealth can also improve communication 
and interaction with the healthcare professionals as well as enhance the opportunity for 
participating in care (Vo et al., 2019). By monitoring the symptoms, patients get the 
opportunity to discuss them with the healthcare professionals, who also can act on them 
within a short period (Drott et al., 2016). This has in patients with different cancer 
diagnoses such as breast, prostate genitourinary, gynecologic, lung, and colorectal cancer, 
lymphoma, and multiple myeloma, been shown to be effective in reducing symptoms, 
improving quality of life and survival (Basch et al., 2016; Denis et al., 2019; Denis et al., 
2017; Ruland et al., 2010). mHealth can also be used to support patients in symptom 
management by providing information and self-care advice (Escriva Boulley et al., 2018; 
Foley et al., 2016; Hernandez Silva et al., 2019; Kearney et al, 2009; McCann et al., 2009). 
2.2.4 Engagement and adherence using mHealth 
As interventions with mHealth to support patients with cancer have increased, it is essential 
to understand how these interventions operate and how usage is experienced and can be 
enhanced to interpret its eventual benefits (Doherty, 2019; Eysenbach, 2005; Gomolin et 
al., 2020; O'Brien et al., 2008; Perski et al., 2017). Usage and user experiences of mHealth 
interventions can be described as engagement (Perski et al., 2017), which is influenced by 
several interacting factors such as a patient’s skills, understanding, demographics, internet 
access, online environment and intervention components such as technical and design 
features. If the patient perceives the interventions as relevant, usable, helpful, and 
interactive, persistent engagement is achieved (Short et al., 2015; Sieverink et al., 2017). 
Related to engagement is adherence, which can be described as the degree to which the 
patients followed or used the intervention as it was planned (Donkin et al., 2011). There are 
several approaches to measure adherence such as number of logins, views on websites and 
modules completed, which depend on the purpose and design of the intervention. High 
levels of adherence within interventions in mHealth have been shown to positively correlate 
with improved outcomes (Donkin et al., 2011). Moreover, high levels of adherence were 
reached in patients with cancer reporting symptoms on a tablet in connection with clinical 
visits (Basch et al., 2017). The need to examine how patients adhere to and perceive 
symptom reporting and monitoring via mHealth when at home between treatments has been 





2.3 The Interaktor app 
The app Interaktor used in the studies focuses on the patient perspective and was inspired 
by different aspects of person-centered care and patient participation in care (Frank, Asp, 
Fridlund et al., 2011; Olsson et al., 2013). Considering the different needs patients may 
perceive during treatment for cancer, the app was developed with the intention to support 
them in real time with information, provision of self-care advice to manage symptoms and 
easy access to the healthcare professionals. This would reinforce communication and 
interaction with the healthcare professionals as well as enhance patient participation in care. 
 
 
Figure 1. Illustration of the idea of the Interaktor app and web interface (Langius-Eklöf, Crafoord, et 
al., 2017; Sundberg et al., 2015). 
 
The app is interactive and the components are: 1) regular assessment of self-reported 
symptoms, 2) a risk assessment model sending alerts for symptoms of concern, 3) 
continuous access self-care advice and links to relevant websites for additional information, 
4) graphs of reported symptom history, and 5) a connected web interface for the contact 
nurse to monitor the patient’s reports in real time (Figure 1). Interaktor was initially 
developed in a collaboration with the research group and a health management company 
specialized in new innovative care solutions. Further it was developed to be adaptable 
depending on setting and target group. To get access to the app it is downloaded onto a 
smartphone or tablet through the operating systems Android and iOS. To get access to the 
content, an individual log in with username and pin code is required. 
The development and test of Interaktor was underpinned by the framework of the Medical 
Research Council (MRC) for evaluating complex interventions (Figure 2) (Craig et al., 
2013; Medical Research Council, 2000). In relation to the initial phases of the framework, 
Interaktor was developed by 1) identifying existing evidence, defining and understanding 
the problem and the context, 2) feasibility or pilot testing to test procedures, 3) evaluation 
by assessing effectiveness (Craig et al., 2013; Medical Research Council, 2000). In the first 
phase, literature reviews in combination with interviews with patients and healthcare 




Gustavell et al., 2017). In the second phase feasibility studies were made to test Interaktor 
(Sundberg et al., 2015; Gustavell, Langius-Eklöf, et al., 2019). Finally, in the third phase, 
were randomized controlled trials (RCTs) to evaluate the effectiveness of Interaktor 
(Langius-Eklöf, Crafoord, et al., 2017). 
 
Figure 2. Description over the phases of the MRC framework. From A framework for development 
and evaluation of RCTs for complex interventions to improve health by Medical Research Council, 
2000, (https://mrc.ukri.org/documents/pdf/rcts-for-complex-interventions-to-improve-health/). CC BY 
2.0. 
 
Interaktor has been tested in different samples and settings such as in patients with prostate 
cancer undergoing radiotherapy (Hälleberg-Nyman et al., 2017; Langius-Eklöf, 
Christiansen, et al., 2017; Sundberg et al., 2015; Sundberg et al., 2017), pancreatic cancer 
after surgery (Gustavell, Sundberg, et al., 2019; Gustavell et al., 2020) and in older persons 








Patients with breast cancer undergoing chemotherapy usually perceive several distressing 
treatment related symptoms over a long period and often report unmet supportive care 
needs in the management of them. As most patients are treated on an outpatient basis, it is 
necessary for the patients to manage symptoms at home. If these symptoms are not properly 
managed it may result in impaired well-being and reduced quality of life as well as poor 
treatment outcomes if the treatment for example must be delayed or interrupted. The 
contact nurse has the responsibility to promote patients’ health during treatment. Therefore, 
it is imperative to ensure that the patients’ symptoms and supportive care needs are 
identified, assessed, and managed regularly in a timely manner, which requires a well-
functioning communication between the patients and the contact nurse. There is a clear 
increase in patients receiving NACT and new treatments and combinations are constantly 
being developed, which means that the support for the patients must also be adapted to this 
development. There are studies of nursing interventions for supporting patients with breast 
cancer during treatment, but many have different methodological weaknesses such as small 
sample sizes and poor study designs. Moreover, studies regarding patients’ perceptions of 
symptoms and related supportive care needs during NACT are few, which may reflect a 
lack of support services for this population. 
Promising results of, for example, improved symptoms, quality of life and increased 
interaction with healthcare professionals have been seen in patients with cancer who have 
used eHealth as a way of reporting their symptoms to the healthcare professionals. It is 
reasonable to believe that patients undergoing NACT may benefit from using mHealth as 















4 OVERALL AND SPECIFIC AIMS 
The overall aim of the thesis is to evaluate how an interactive app for reporting and 
managing symptoms provides supportive care in patients with breast cancer during 
neoadjuvant chemotherapy.  
The thesis is based on three studies with the following aims: 
Study I 
The aim was to evaluate whether the use of the interactive app Interaktor improves patients’ 
levels of symptom burden and health-related quality of life during neoadjuvant 
chemotherapy for breast cancer. 
Study II 
The aim was to describe engagement with the Interaktor app among patients with breast 
cancer during their treatment. 
Study III 
The aim was to describe patients’ perceptions of care with or without the support of an 







The design for this thesis originates from one randomized controlled trial (RCT) including 
both quantitative and qualitative approaches. The first study is experimental, where effects 
of the intervention are assessed and evaluated. The second study involves both a 
quantitative and qualitative approach to describe the patients’ engagement in the 
intervention. The third study has a qualitative approach of patients' perceptions of care and 
use of the intervention. An overview of the included studies, samples, and the methods used 
for data collection and analyses are presented in Table 2. 
 
 














Patients with breast cancer 
undergoing NACT (n=149) 
- Intervention group n = 74 
- Control group n = 75 
 
Sociodemographic and clinical data 
MSAS 
EORTC QLQ-C30 




Student’s t test 
Chi-square test 






Patients with breast cancer 
undergoing NACT (n=74) 





Sociodemographic and clinical data  
Logged data from app usage 
Structured individual interviews 
 
Descriptive statistics 
Mann-Whitney U test 
Chi-square test 
Fischer’s exact test 
Multiple regression analysis 





Patients with breast cancer 
undergoing NACT (n=40) 
- Intervention group n = 21 
- Control group n = 19 
 
 
Sociodemographic and clinical data  







RCT=Randomized controlled trial; MSAS=Memorial Symptom Assessment Scale; EORTC QLQ-C30 = European 
Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire; ANCOVA = Analysis of covariance 
 
* = Population is not included in this thesis 
 
 
5.2 Interaktor – Breast cancer – NACT version 
The content of the app for patients with breast cancer during NACT needed to capture 
symptoms important to patients and healthcare professionals. This version of Interaktor was 
developed in two phases. In the first phase, a review of literature was conducted regarding 
current research and prevailing clinical guidelines concerning symptoms, symptom 
management and self-care advice associated to breast cancer and NACT, as well as 
discussions with the healthcare professionals at the clinics. In the second phase, the app was 
pilot tested during April 2015 in eight patients and interviews were conducted with both 




of the RCT. The optimization concerned adjustments of alerts levels, changes and 
corrections of texts for some self-care advice, addition of self-care advice, adjustments in 
the web interface to make the patients reports more manageable. An illustration of 
screenshots from the patient view in the final version of the app is presented in Figure 3. 
 
Figure 3. Screenshots of the Interaktor app adapted for patients with breast cancer undergoing 
NACT. 
 
5.2.1 Symptom reporting 
The symptom reporting questions are inspired by a standardized questionnaire assessing 
different dimensions of symptoms perceived by patients undergoing treatment for cancer 
and they address prevalence, frequency and distress level of symptoms perceived during the 
last day (Portenoy et al., 1994). For example, “Have you perceived nausea in the last 24 
hours?” If the answer is “yes”, the patient is asked about how often the symptom is 
prevalent by rating the frequency (almost always, often, sometimes and almost never) 
followed by how distressing the symptom is by rating distress level (very much, rather 
much, a little and not at all). The reported symptoms are immediately transferred via a 
secure server approved by the Swedish Data Protection Authority, to a linked web interface 
where the contact nurse can monitor the patient’s reports in real time. Reporting in the app 




reports. If a report has not been submitted before 2 p.m., a notification is sent out to remind 
the patient to report. 
The app contains assessment of 14 self-reported symptoms commonly prevalent during 
chemotherapy such as fever, breathing difficulties, pain in the body, numbness/tingling in 
hands and feet, nausea, vomiting, diarrhea, constipation, oral problems, depression, 
anxiety/worry, fatigue, sleeping difficulties, and swelling/pain/redness in the arm (related to 
the peripherally inserted central catheter line for chemotherapy administration). 
Furthermore, a free text message question “Other symptoms or concerns to report?” is 
included. The symptoms fever and pain/swelling/redness in the arm are only assessed by 
reporting prevalence. The symptoms constipation, oral problems, depression, 
anxiety/worry, and sleeping difficulties are only assessed by reporting distress level. 
5.2.2 Alerts 
The alerts in the risk assessment model are triggered depending on how the symptom is 
reported by the patient according to level of prevalence, frequency, and distress. All alerts 
are triggered after a report. Symptoms and their levels set to generate alerts in this version 
are shown in Table 3. There are two kinds of alerts, yellow and red. Yellow alerts are sent 
when symptoms are less severe and require a contact nurse to contact the patient during the 
day, and red alerts are sent in cases of greater severity, and require contact within one hour 
since this can mean a potential risk to the patient’s health and wellbeing. The alerts are sent 
to a mobile phone at the clinic by text message (SMS), which leads to a contact nurse 
contacting the patient to discuss the symptom and further actions. The alerted symptom for 
each patient can be viewed in the web interface as well as being documented regarding the 
actions taken after an alert. The symptoms numbness/tingling in hands and feet, fatigue and 
sleeping difficulties are not set to trigger alerts. Often these symptoms are perceived 
frequently over a long period and could therefore lead to triggering alerts with each 
submitted report. Moreover, even though those symptoms can be perceived as distressful by 













Table 3. The risk assessment model for symptoms set to generate alerts in the version of Interaktor for 

















Breathing difficulties Frequency  “Often” 




Pain in the body Frequency  “Almost always” Yellow 
 
Numbness/tingling in hands and feet N/A N/A 
 
Nausea Frequency  “Often” 




Vomiting Frequency  “Often” 




Diarrhea Frequency  “Almost always” Yellow 
 
Constipation Distress “Very much” Yellow 
 
Oral problems Distress “Rather much” Yellow 
 
Depression Distress “Very much” Yellow 
 
Anxiety/worry Distress  “Very much” Yellow 
 
Fatigue N/A N/A 
 
Sleeping difficulties N/A N/A 
 
Swelling/pain/redness in the arm Occurrence “Yes” Yellow 
 
 
N/A = Not applicable means that no alert is triggered for the symptom. 
 
 
5.2.3 Self-care advice and symptom history graphs 
In the app, the patient has continuous access to 17 evidence-based self-care advice, as well 
as links to relevant websites with information related to assessed symptoms and other areas 
of concern. If an alert is triggered, a notification suggests to the patient to read related self-
care advice. Moreover, the patient has the possibility to monitor own reported symptom 
history over time in graphs (Figure 3). 
 
5.3 Setting and sample (Studies I – III) 
In Stockholm region, investigation and treatment of breast cancer is performed at three 
breast centers: Karolinska University Hospital, Södersjukhuset and Capio St. Göran 
Hospital. The breast centers focus on the patient’s path through the care from screening and 
diagnostics, through treatment to rehabilitation and follow-up (Regional Cancer Center 
Stockholm-Gotland, 2018). Recruitment and inclusion of the patients were performed at the 





Figure 4. Samples in respective studies. 
 
In Study I, the sample size was calculated from the results of a previous study on patients 
with prostate cancer (Sundberg et al., 2017) as there were no data in this population. With 
an effect size (Cohen’s d) difference of 0.54 at the end of treatment in the primary outcome 
of symptom burden with 90% power at P < 0.05, 71 patients in each group were estimated 
in this study. Between June 2015 and March 2017, 204 patients newly diagnosed with 
breast cancer and planned for NACT were found to be eligible when screened through the 
medical appointment lists. Inclusion criteria were patients aged over 18 years, diagnosed 
with non-metastatic breast cancer and able to read and understand Swedish. Exclusion 
criteria were patients with a documented cognitive dysfunction. When asked about 
participation, 47 patients declined, and seven patients could not be reached. In total, 150 
patients were consecutively included for randomization in the study. The patients were 
equally randomized into an intervention group or a control group. One patient in the 
intervention group was excluded after randomization and introduction to the app due to a 
change of treatment to primary surgery instead of NACT. The final sample therefore 
consisted of 74 patients who received the intervention in combination with standard care 
and 75 patients who received standard care alone (control group) (Figure 4). 
Study II includes 74 patients from the intervention group who used the app. Of those 73 
patients were interviewed, as one patient declined to participate in the telephone interview. 




on patients with locally advanced prostate cancer during treatment with radiotherapy. The 
two RCTs were conducted simultaneously, however, this thesis only reports on the sample 
consisting of patients with breast cancer undergoing NACT. 
Study III includes 21 patients from the intervention group and 19 from the control group. 
Initially, a consecutive sampling strategy with an equal number of patients from both the 
intervention group and the control group at the two hospitals was adopted in the first 20 
patients. To capture a range of patients’ characteristics such as age at inclusion, residential 
area, marital status, highest education level, occupation and treatment duration in weeks, a 
strategic sampling was then used in the remaining 20 patients from both groups at the 
hospitals. Four patients declined to participate in the face-to-face interviews (intervention 
group n = 2 and control group = 2). 
 
5.4 Standard care 
In Sweden, all patients diagnosed with breast cancer are discussed at a multidisciplinary 
conference (MDC). During an MDC, various professions responsible for the patients’ care 
are gathered to discuss appropriate treatment to gain best treatment results (Confederation of 
Regional Cancer Centres in Sweden, 2020b). 
Patients who have been recommended NACT during an MDC have their initial visit with a 
physician at the oncology clinics. According to a standardized care process for breast cancer, 
NACT starts approximately two weeks after the patients are diagnosed. During the treatment 
period, the patients have visits with the physician before each chemotherapy treatment to 
assess the patients’ health status and the tumor response to the treatment. Most patients 
undergoing chemotherapy for breast cancer are treated on an outpatient basis, which means 
that they receive their treatment at the oncology clinic and then return home between 
treatments (Confederation of Regional Cancer Centres in Sweden, 2020b). 
5.4.1 Contact nurse  
According to the National Cancer Strategy for the Future (The Swedish Government Official 
Reports, 2009), it has been decided that all patients diagnosed with cancer shall be assigned a 
contact nurse within the clinic where the care takes place. According to Confederation of 
Regional Cancer Centres in Sweden, 2020b, the purpose of the contact nurse is to guide and 
support the patients through investigation, treatment, and rehabilitation, to improve both 
information and communication between the patients and healthcare professionals 
(Confederation of Regional Cancer Centres in Sweden, 2020b). Before the patients started 
NACT, they were assigned a contact nurse with whom the patients had a visit either directly 
after the initial visit with the physician or booked a couple of days after the consultation with 
the physician, depending on the routines at the respective clinic. During these visits to the 
contact nurse the patients were given verbal and written information about NACT, related 




appointments to the physician and treatments, information about the peripherally inserted 
central catheter line, where to get a wig, sickness payment, healthcare journeys and 
psychosocial contact. The patients were also offered a guided tour to orientate themselves 
better at the clinic. Contact information was given to all patients where to call during all 
hours of the day and to contact the emergency department in case of severe symptoms related 
to the treatment. If the patients had questions or other concerns related to the treatment, they 
were encouraged to call their contact nurse at the clinic during working hours on weekdays (8 
a.m. to 4 p.m.) or recommended to use an online eHealth system “1177 Vårdguiden”, 
offering different services for information, advice or contact with healthcare (Confederation 
of Regional Cancer Centres in Sweden, 2020b). 
 
5.5 Procedure (Studies I – III) 
During the patients’ first visit at the oncology clinics, they received written information 
about the study from the assigned oncology contact nurse or physician. The patients were 
then contacted by the researcher and asked about participation. For patients who agreed to 
participate, a meeting was arranged with the researcher before starting NACT. During this 
meeting, the patients filled in informed consent and a baseline questionnaire. Subsequently, 
randomization was performed by sequentially drawn opaque sealed envelopes containing a 
card with the treatment allocation. The envelopes were opened in front of the patient. Prior 
to the randomization process, the envelopes had been shuffled by an independent 
individual. Depending on which group the patients were randomized to, more detailed 
study information was given to the patient. Both groups of patients received standard care 
and only the intervention group reported in the app (Figure 5). 
 
 
Figure 5. Flowchart of the procedure for study I-III. 
 
The patients in the intervention group were individually informed how to use Interaktor 
both verbally and in writing. Patients who had their own access to a smartphone or tablet 
got help to download the app on their device and received an individual login for access to 
the content of the app. Two patients borrowed a smartphone from the research group to use 
during the study period. The patients were shown how to report symptoms in the app and 
were shown the self-care advice and the graphs of previous reports. A detailed written 




well as contact information to the researcher in case of questions or concerns about the app 
and the study. The patients were instructed to submit a report at least once a day on 
weekdays starting on their first day of NACT and continuing until two weeks after end of 
NACT. Total reporting time was approximately 18 weeks. Furthermore, patients were 
carefully informed that the contact nurses at the clinic would monitor and respond to alerts 
triggered during working hours (8 a.m. to 4 p.m.) on weekdays and in case of an alert they 
would only be contacted during these hours. If emergency healthcare attention was needed 
outside these hours, the patients were instructed to contact the clinic according to standard 
care procedure. To be able to monitor and manage the patients reports and alerts, the 
contact nurses at the clinics received brief training on how to use the connected web 
interface before the RCT started. This training consisted of an individual overview with 
each contact nurse where they were provided verbal and written instructions on how to use 
the web interface as well as practical exercises on fictitious patients. 
All patients were informed about the respective follow-up procedure according to the group 
they were allocated to. After the end of reporting, telephone interviews were conducted 
with the patients in the intervention group. Further, questionnaires to be filled in two weeks 
after end of NACT in both the intervention and control group as well as individual face-to-
face interviews with a sample of patients from both the intervention and control group 
conducted three months after end of NACT. When the patients agreed to take part in the 
RCT, they had been informed they could later be contacted and asked to participate in 
interviews. 
As the study was ongoing, NACT occasionally had to be interrupted for some patients. This 
was due to several reasons such as no tumor response during treatment (intervention group 
n = 2, control group n = 3), or too severe symptoms to continue the treatment (intervention 
group n = 5, control group n = 3). In these cases, surgery was performed earlier than 
planned. If it was detected that patients’ disease had spread, this led to a switch of treatment 
to other chemotherapy agents or anti-hormonal treatment. This was detected in six patients 
(intervention group n = 2, control group n = 4) after cycle two to six depending on 
chemotherapy regimen. The study procedure during these circumstances was that patients 
who had surgery performed earlier reported in the app until the day before surgery 
(intervention group) and had the follow up questionnaire sent out according to original 
planning (intervention and control group). Patients with detected spread of disease reported 
in the app (intervention group) and had the follow-up questionnaire sent out according to 
the original planning (intervention and control group), thus two weeks after when it was 
planned that the NACT would end. 
 
5.6 Data collection (Studies I – III) 
The overall project includes different sets of data: sociodemographic and clinical data of 




data on the patients’ app usage and individual interviews concerning perceptions of using 
the app as well as perceptions of care with or without using the app. 
Sociodemographic data including age, residential area, marital status, education level and 
occupation was obtained from the baseline questionnaires. Clinical data concerning 
menstruation status, tumor characteristics such as histologic grade of the tumor (Elston-
Ellis), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and 
progesterone receptor (PR) status, proliferation rate (Ki-67), type of chemotherapy regimen, 
treatment duration in weeks, completion of planned cycles of NACT and reasons for early 
treatment discontinuation, were obtained from the electronic medical records. Any medical 
conditions of each patient were also collected at baseline from the electronic medical 
records to calculate comorbidity score using Charlson Comorbidity Index (CCI). 
Comorbidity score predicts mortality in patients with a range of different comorbidities. 
The CCI encompasses 19 medical conditions related to heart, liver, kidney and lung 
disease, cerebrovascular disease, dementia, diabetes, malignancies, and AIDS. Each 
condition has a score based on a relative risk of death within a year. The scores are totaled 
to yield the comorbidity score, with a range between 0 and 37. A higher value corresponds 
to greater comorbidity (Charlson et al., 1987). 
In Study I, symptoms were assessed through self-reported questionnaires at baseline before 
randomization, and two weeks after end of NACT by using the Swedish version of The 
Memorial Symptom Assessment Scale (MSAS) (Browall et al., 2013), which was 
developed to measure the multidimensional perception of 32 common cancer-related 
symptoms in oncology patients (Portenoy et al., 1994). Twenty-four symptoms assess 
prevalence (if a symptom is present or not), frequency (how often it is present), severity 
(how severe the symptom is perceived) and distress (how bothersome the symptom is 
perceived). Eight symptoms assess only prevalence, severity, and distress. Each symptom is 
rated as being present (0) or absent (1) during the past week. If a symptom is present, 
frequency and severity are rated on a four-point rating scale from 1 = rarely to 4 = almost 
constantly and distress on a five-point rating scale from 0 = not at all to 4 = very much. 
Higher scores indicate greater frequency, more severity and higher distress. The MSAS also 
features four subscales: Global Distress Index (MSAS-GDI), which measures overall 
symptom distress, includes the average of the frequency of four psychological symptoms 
(feeling sad, worrying, feeling irritable and feeling nervous) and the distress of six physical 
symptoms (lack of appetite, lack of energy, pain, feeling drowsy, constipation and dry 
mouth). The Physical Symptom Subscale (MSAS-PHYS), which measures physical 
symptoms, includes the average of the frequency, severity and distress of 12 symptoms 
(lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry mouth, nausea, 
vomiting, change in taste, weight loss, feeling bloated and dizziness). The Psychological 
Symptom Subscale (MSAS-PSYCH), which measures psychological symptoms includes 
the average of the frequency, severity and distress of six symptoms (worrying, feeling sad, 
feeling nervous, difficulty sleeping, feeling irritable and difficulty concentrating). Total 




average of the symptom scores of all 32 items including frequency, severity and distress. 
The MSAS has been widely used in clinical trials to assess symptoms and is therefore well-
validated and reliable (Browall et al., 2013; Portenoy et al., 1994). To ensure reliability, 
internal consistency was measured for all subscales by using Cronbach’s reliability 
coefficient α. All subscales showed a Cronbach’s alpha of > 0.80 at baseline and two weeks 
after treatment completion, which was considered as acceptable (Field, 2017). 
Health-related quality of life was assessed through self-reported questionnaires at baseline 
before randomization, and two weeks after end of NACT by using the Swedish version of 
The European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30) (version 3.0), which measures health-related 
quality of life during the past week (Aronson et al., 1993). The questionnaire includes 30 
items, where 28 of them have four response alternatives: not at all, a little, quite a bit and 
very much. Two (2) of the items have seven response alternatives from very poor to 
excellent. Furthermore, the 30 items are divided into one global health status scale/quality 
of life, five functional scales exploring physical, role, emotional, cognitive and social 
functioning, as well as eight symptom scales assessing fatigue, nausea/vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation and diarrhea and one item measuring 
financial impact. A high score in the global health and functional scales represents a high 
level of health-related quality of life and functioning, whereas a high score in each of the 
item and symptom scales represents high levels of symptoms or problems (Aronson et al., 
1993). This instrument is widely used, well validated and has shown good reliability for 
assessing health-related quality of life in patients with cancer (Aronson et a., 1993; Sitlinger 
& Zafar, 2018). Internal consistency was measured for all subscales by using Cronbach’s 
reliability coefficient α. All scales showed a Cronbach’s alpha of > 0.72 at baseline and two 
weeks after treatment completion, which was considered as acceptable (Field, 2017), except 
for nausea/vomiting at baseline (α = 0.47) and after treatment completion (α = 0.61).  
For Studies I and II, logged data was collected through app usage and included the 
patients’ submitted reports, symptoms reported, triggered alerts, views of self-care advice, 
and free text messages sent. The logged data was hosted on a secure server and was 
accessible and extracted in an encrypted Microsoft Excel 2013 file. At the time of this RCT, 
it was not possible to log data on clicked links or viewed graphs for later retrieval. 
In Study II, individual telephone interviews were conducted with the patients in the 
intervention group after their final report in Interaktor, about perceptions of using the app. 
A semi-structured interview guide was used focusing on patients’ perceptions of usability 
and utility of using the app and its components. Questions such as “What was it like to 
report in the app?” and “How have you experienced that the technology has worked” were 
asked as well as questions specifically related to the components of the app such as “Have 
you used the self-care advice?” and “Have you used the graphs to follow your symptom 
history?” Follow-up questions were used to deepen the patients’ responses. The telephone 




10 and 20 minutes, during which notes of the answers were made in the template of the 
interview guide. All telephone interviews were conducted by the author of this thesis. 
For Study III, individual face-to-face interviews were conducted three months after end of 
NACT with patients from both the intervention and the control group. The interviews took 
place in a secluded room at both oncology clinics and followed a semi-structured interview 
guide covering different aspects of patient participation such as the relationship between 
patient and the healthcare professionals, patients’ information needs, self-care, and 
caretaking (Angel & Fredriksen, 2015; Frank, Fridlund, Baigi, et al., 2011). Examples of 
questions asked to the patients were “How did you perceive the contact (care relationship) 
between you and the healthcare professionals during the treatment period?”, “Do you feel 
that you have received enough information regarding your care and treatment?” and “How 
have you experienced your encounters with the healthcare professionals?”. In addition, the 
patients in the intervention group were asked about the significance of using the app during 
the treatment. The patients were requested to speak as freely as possible and depending on 
the extent of their answers, follow-up questions were used to get more in-depth responses 
from the patients. The interviews were audio-recorded and lasted between 14 and 61 
minutes, with a median of 27 minutes. All interviews were conducted between January 
2016 and August 2017 and the majority of them were conducted by the author of this thesis. 
 
5.7 Data analyses (Studies I – III) 
The statistical analyses were performed using IBM Statistical Package for Social Sciences 
(SPSS) version 24, Windows version. A p-value < 0.05 was considered as statistically 
significant in all analyses. 
In Studies I and II, descriptive statistics were used to analyze the sociodemographic and 
clinical data. Between-group analyses were performed using Chi-square and Fisher’s exact 
tests for categorical variables and Student’s t-test for continuous variables. For continuous 
variables that were not normally distributed (Study II), Mann-Whitney U test was used. 
In Study I, the items in the MSAS questionnaire were processed according to Portenoy et 
al. (1994). In the initial step, a score (MSAS score) for each symptom is calculated. If a 
symptom is absent, the score for that is 0. If a symptom is present, the score is 1. To 
determine the MSAS score for each present symptom, the average of the scores on 
frequency, severity and distress for the symptom is calculated. This initial calculation forms 
the basis for further calculation of the MSAS subscales. Percentages were calculated of the 
prevalence of the symptoms between the intervention group and control group at baseline 
and two weeks after end of NACT by using Chi-square test. When analyzing health-related 
quality of life, the items in EORTC QLQ-C30 were processed according to the EORTC 
QLQ-C30 scoring manual (Fayers et al., 2001). The principle for scoring in all scales is the 




raw score. Thereafter the raw scores are linearly transformed so that the scores range from 
0 to 100. 
At baseline there were no questionnaires or single items missing in MSAS and EORTC 
QLQ-C30. At two weeks after end of NACT, some patients were lost to follow-up in both 
groups. Five questionnaires were missing in the intervention group (6.8%) and four 
questionnaires in the control group (5.3%). To handle missing data, a modified intention-to-
treat (ITT) approach was used, which allows exclusion of randomized patients if it is 
justified (Abraha & Montedori, 2010; Gupta et al., 2011; Montedori et al., 2011; Polit & 
Gillespie, 2010). This was the case in this RCT, since one patient was excluded after being 
ineligible after randomization and therefore not included in the analyses. Missing values in 
MSAS and EORTC QLQ-C30 at two weeks after end of NACT were replaced with the 
baseline values using the baseline observation carried forward method (BOCF) (Liu-Seifert 
et al., 2010; Petroff, 2017). Complete case analyses were also performed for MSAS and 
EORTC QLQ-C30 to make the results from both approaches visible. 
To assess between-group differences in MSAS and EORTC QLQ-C30, analysis of 
covariance (ANCOVA) was used adjusting for baseline values. 
To calculate the magnitude of the effect between the two groups, Cohens d effect size (ES) 
was calculated by subtracting the group means and dividing the result by the pooled standard 
deviation (intervention group mean – control group mean/SDPooled). A value of 0.2 – 0.5 is 
often interpreted as small effect, 0.5 – 0.8 as medium effect and ≥ 0.8 as large effect (Cohen, 
1988; Sullivan & Feinn, 2012). 
In Studies I and II, the logged data of the patients’ app usage during treatment concerning 
submitted reports, triggered alerts, views on self-care advice, and free text messages sent, 
were analyzed with descriptive statistics using Microsoft Excel 2013. Adherence to report 
was calculated as the number of weekdays a patient submitted a report (excluding multiple 
daily reports) divided by the number of weekdays a patient was intended to report. 
Adherence was presented as a mean percentage for the whole group. 
To investigate whether age, comorbidity, marital status, and education level predicted usage 
variables of the app such as adherence to daily reporting as intended, total number of alerts 
triggered, total views on self-care advice, and total number of free text messages sent, 
multiple regression analysis was conducted. Marital status was dichotomized and coded as 
single/living apart = 0 and married/cohabiting = 1. Education level was dichotomized and 
coded as high school/secondary school = 0 and college/university = 1. Since all usage 
variables were positively skewed, these were normalized using natural log transformation 
(loge) (Altman, 1990). 
The telephone interviews concerning perceptions of using the app were analyzed with an 
inductive approach using conventional content analysis (Hsieh & Shannon, 2005). First, all 




was compiled with the patients' answers. The data sheet was reviewed repeatedly, and 
systematically coded. Thereafter, the codes were sorted based on similarity into 
subcategories and combined based on content into overarching categories. During the 
analytical process, the authors of the study continuously discussed and reviewed the 
analysis to come to a consensus. 
In Study III, the face-to face interviews concerning patients’ perceptions of care with or 
without using Interaktor were analyzed with an inductive approach using thematic analysis 
as described by Braun and Clarke (2006). First, the recorded interviews were transcribed 
verbatim and the texts were read through several times to become familiar with the data and 
the whole. Initially each group was analyzed separately, starting with the intervention 
group, followed by the control group. Statements from the patients regarding perceptions of 
care and the app were systematically coded throughout the entire dataset and transferred 
into a coding sheet. A code could consist of a few words or a whole sentence. After the 
statements from the two groups had been coded, the codes were then discussed between the 
authors of the study. Since there were mainly similarities in the statements between the two 
groups, the codes were merged into one coding sheet and tagged with an identification so 
that they could be distinguished according to group. Analysis continued by sorting and 
putting together similar codes from both groups and themes were created. The codes 
included in each theme were then reviewed to see if the theme worked well in relation to 

















6 ETHICAL CONSIDERATIONS 
In this thesis, all studies were carried out according to the ethical principles of the Helsinki 
Declaration (World Medical Association, 2013) as well as The Act concerning the Ethical 
Review of Research Involving Humans (SFS 2003:460) (The Swedish Riksdag, 2003). 
Central in the Helsinki Declaration is that there must be a balance between the benefits of 
the research and the protection of the participants. Further, the participants’ right to 
autonomy, justice and informed consent must be ensured. In RCTs, it is also of importance 
that the intended participants are informed about the procedure and its purpose, as well as 
understand what it means to be randomized to an intervention or control group. The Act 
concerning the Ethical Review of Research Involving Humans involves managing personal 
data considered to be sensitive information. Furthermore, there are several ethical 
considerations that need to be made when using mHealth in research, such as the large 
volumes of data from the patients, which need to be stored and managed so as to ensure 
anonymity and confidentiality. Access to mHealth, regardless of socioeconomic status or 
physical or mental impairments, and evaluation of safety and effectiveness are also 
important considerations (Botrugno, 2019; Carter et al., 2015). All studies included in this 
thesis have also undergone ethical examination and were approved by The Regional Ethical 
Review Board of Stockholm, Sweden (Reg.no: 2013/1652-31/2) and (Reg.no: 201712519-
32). 
In Studies I – III, the patients received written information about the study in connection 
with their first visit to the oncology clinic. A couple of days later, the patient was contacted 
by a researcher who answered any questions about the study and asked if the patient wanted 
to participate. For patients who agreed to participate, a meeting was arranged prior to the 
start of NACT. At the meeting, the patients signed a written informed consent and were 
informed that participation was voluntary and that they could withdraw from the study at 
any time without specifying a reason, which would not influence the forthcoming care and 
treatment. Further specific verbal and written information was given to the patients 
depending on which group they were randomized into, such as how to use the app and what 
the follow-up meant in terms of questionnaires and interviews. 
The patients were also informed that all collected data would be handled confidentially. To 
avoid potential threats to autonomy and integrity, the inclusion process and data collection 
were performed by researchers who were not involved in the patients’ care. As the patients 
had been randomized, they were given a specific individual code. When analyses of the 
data were performed it was therefore not possible to determine which ratings or statements 
had been made by a specific patient. Also, the results are presented so that individual 
patients cannot be identified. All collected data was stored and accessible only to 
researchers involved in the RCT. The list of the codes was stored separately from the other 
collected data to prevent the identity of the patients from being revealed. 
Patients who were randomized to use the app and did not have access to a smartphone or 




who used the app were provided an individual login with username and password to get 
access to the content in the app, and the contact nurses who monitored the reports received 
a username and password to get access to the web interface. Besides app usage, the 
patients’ names and personal identity number were registered in the web interface to ensure 
easy access for the contact nurses to the patients’ medical records. Involved researchers had 
access to the web interface for registering new patients and for monitoring at regular 
intervals to ensure that alerts had been responded to. Appointed staff at Health Navigator 
(the company who assisted with the development of Interaktor) also had access to the web 
interface for technical support. The data from the use of the app and web interface was 
logged and stored on a secure server hosted by Health Navigator. The server was approved 
by The Swedish Data Protection Authority. To prevent personal information from the 
logged data being disclosed to unauthorized persons, data files were encrypted when sent 
from Health Navigator to the researchers for data management.  
It posed no risks for the patients to participate in the RCT. All patients received standard 
care and the patients who were randomized into the intervention group used the app as a 
complement to standard care. The patients were instructed to report during office hours and 
were carefully informed who to contact if any severe symptoms or problems related to the 
treatment occurred outside these hours. The patients were also encouraged to contact the 
researcher in case of questions or concerns regarding the study. There was also knowledge 
among the researchers to refer the patients’ further if such needs arose, for example if a 
researcher was contacted by the patients in case of severe symptoms or need for contact 
with the healthcare professionals. 
Research such as this RCT involves patients who are in a vulnerable situation. Not only do 
they have a potentially life-threatening illness. They may also experience multiple 
distressing symptoms and concerns related to both illness and treatment and at the same 
time struggle to make everyday life work. Therefore, it is fundamental that research is 
conducted in an ethical way. For example, when being interviewed about personal 
perceptions of the app and care, this can be sensitive and trigger unpleasant emotions and 
memories. There was an awareness about this as the researcher had extensive experience of 
working with this group of patients. It is also important to recognize that patients treated at 
larger oncological clinics at university hospitals are often asked to participate in several 
studies at the same time. This implies a risk that the patients become burdened with 
different studies because they feel obliged to participate in research as they might feel 
dependent on the healthcare professionals. Also, patients planned for NACT often start the 
treatment shortly after being diagnosed, which means they have limited time to think and 
make a decision to participate in the study. On the other hand, it would be unethical to not 
ask all eligible patients about participation. Therefore, the need for sufficient information 






7 RESULTS (STUDIES I – III)  
This section contains a summary of the results from all three studies conducted in Phase III 
(Definitive RCT) in the MRC framework (Craig et al., 2013; Medical Research Council, 
2000). More detailed results of each study are presented in the publications attached in the 
last section of this thesis. 
7.1 Sociodemographic and clinical data (Study I) 
In Study I, there were no statistically significant differences between the intervention group 
and the control group in sociodemographic and clinical data at baseline (Table 4). The 
average treatment duration of NACT in both groups was 15 weeks (Intervention group SD 
= 4.77, range = 3-34; Control group SD = 2.60, range = 3-26). Further, most of the patients 





























(n = 75) 
 
 
Age at inclusion, years  
  
Mean (SD) 48 (10.6) 50 (11.6) 
Range 27-73 30-77 
   
Marital status, n (%)   
Married/Cohabiting 61 (82.4) 57 (76.0) 
Living alone 13 (17.6) 18 (24.0) 
   
Highest education level, n (%)   
University 50 (67.6) 44 (58.7) 
Secondary school 18 (24.3) 25 (33.3) 
Primary school 6 (8.1) 6 (8.0) 
   
Occupation, n (%)   
Working 57 (77.0) 48 (64.0) 
On sick leave 12 (16.2) 14 (18.7) 
Retired/Unemployed 5 (6.8) 13 (17.3) 
   
Type of chemotherapy and combinations, n (%)    
EC 3 (4.1) 1 (1.3) 
EC + DOC or EC + weekly Paclitaxel or TAC 37 (50.0) 38 (50.7) 
FEC + DOC or FEC + weekly Paclitaxel 9 (12.2) 13 (17.3) 
Gemcitabine + Carboplatin 2 (2.7) 1 (1.3) 
DOC or weekly Paclitaxel 11 (14.9) 14 (18.7) 
DOC + Carboplatin 1 (1.4) 0 (0) 
DOC + Trastuzumab Emtansine 2 (2.7) 2 (2.7) 
Trastuzumab Emtansine 9 (12.2) 6 (8.0) 
Abbreviations 
EC = Epirubicin, Cyclophosphamide 
DOC = Docetaxel 
TAC  = Docetaxel, Doxorubicin, Cyclophosphamide 





7.2 Impact on symptoms and health-related quality of life (Study I) 
Before start of NACT, the intervention group rated statistically significant higher 
prevalence of difficulty sleeping (p =.047) and lower prevalence of difficulty swallowing (p 
= .044) than the control group. In the MSAS subscales there were no statistically significant 
differences between the groups before start of NACT. At two weeks after end of NACT the 
intervention group rated statistically significant lower prevalence in nausea (p = .041), 
vomiting (p = .037), and feeling sad (p = .003) compared with the control group. In the 
subscales of MSAS, overall symptom distress (MSAS-GDI), was rated statistically 
significant lower in the intervention group (p = .004, d = 0.34) than in the control group. 
Regarding physical symptoms (MSAS-PHYS), the intervention group rated statistically 
significant lower levels (p = .031, d = 0.27) in comparison with the control group. Further, 
the intervention group rated statistically significant lower scores in the total MSAS (p = 
.033, d = 0.26) than the control group did. In the subscale measuring psychological 
symptoms (MSAS-PSYCH), there were no statistically significant differences between the 
groups. 
There were no statistically significant differences between the intervention group and the 
control group in the EORTC QLQ-C30 at baseline. At two weeks after end of NACT, the 
intervention group rated statistically significant higher emotional functioning (p = .008, d = 
0.30) than the control group. In the remaining four functional scales: physical, role, 
cognitive and social scale, there were no statistically significant differences between the 
groups. In the symptoms scales the intervention group rated statistically significant lower 
levels in nausea and vomiting (p = .007, d = 0.40), appetite loss (p = .027, d = 0.35 ), and 















7.3 Logged data from app usage (Studies II and III) 
The patients used the app for a median of 106 days (range 22-183 days). The median 
adherence to report symptoms was 83% (Study II). 
In Study I, the patients using the app reported a total number of 15386 different symptoms 
during the study period. Fatigue was the most reported symptom (n = 3591), followed by 
oral problems (n = 1847), and sleeping difficulties (n = 1764) (Figure 6). Each patient 
reported on average two prevalent symptoms per day. 
 
 
Figure 6. Distribution of the total number of reported symptoms during the study period (n = 15386). 
 
In total, 71 out of 74 patients (96%) triggered at least one alert with a median of 7 alerts 
(range 1-210) during the study period. Of the triggered alerts 1094 (86%) were yellow and 
182 (14%) were red. 
All patients viewed the self-care advice in the app at least once with a median of 11 various 
self-care advice out of the 17 self-care advice available. The total number of views were 
1075 of which 362 (34%) were made after the patients had been notified in the app with 
suggestions to read related self-care advice when an alert was triggered. The most common 
self-care advice viewed were related to oral problems (n=196), nausea (n=126) and pain 






Figure 7. Distribution of the total number of self-care advice viewed during the study period             
(n = 1075). 
 
The free text function was used by 93% of the patients and concerned symptoms which 
were not assessed in the app, requesting or declining contact, care-related information, and 
issues linked to the app or to reporting. The use of the function varied. Some patients wrote 
short messages, while others wrote long descriptions. 
 
7.4 Predictors of app usage (Study II) 
The multiple regression showed that none of the regression models in the analysis was 
statistically significant, meaning that patients characteristics age, comorbidity, marital status, 
and education level did not predict usage of the app (adherence to daily reporting as intended, 
total number of alerts, total views on self-care advice, and total number of free text messages 
sent). Only one single characteristic; higher age predicted a decreased total number of free 
text messages sent (p  = .040)*.  
*Misprint in the published paper “Engagement in an interactive app for symptom self-management during 
treatment in patients with breast or prostate cancer: mixed methods study” (Study II). 
 
7.5 Perceptions of using the Interaktor app (Study II) 
The patients expressed that the app was easy to use with few technical problems during the 
study period and went quick to report in. The content in the app was considered by most of 
the patients as relevant. They described that the symptom assessment component included 
most of their perceived symptoms during treatment and reporting went quick. Some 
patients lacked symptoms to report such as headache and the symptom pain was considered 




symptoms or other concerns to the contact nurse. There were discrepancies in how patients 
perceived to report in the app on a daily basis. Many patients described symptom reporting 
as a way of keeping a diary, which made them reflect on their wellbeing as well as 
becoming aware of symptoms. Most patients considered reporting as more necessary during 
days when they felt ill, however it could sometimes be stressful. A few patients described 
that reporting in the app during days when they felt well was a negative reminder of their 
illness. During these days it could also be difficult to remember to report and therefore the 
reminder notification was appreciated. Using the graphs also enabled self-monitoring of 
reported symptoms. Patients perceived the graphs as useful for comparing symptoms and 
detecting patterns in symptoms over time, which facilitated planning of activities during 
days when they felt well. The graphs also made it visible that many days were trouble-free. 
Most patients who used the app described it as a facilitator for support during NACT. 
Reporting symptoms and in case of an alert being called by a contact nurse was perceived 
as having a continuous, close, and interactive contact with the contact nurse, which created 
feelings of being monitored, safe, acknowledged and cared for. It also decreased the need 
for patients to contact the clinic by themselves, where they had to search for the right 
number to call or be put on hold. However, there were some patients who expressed wishes 
that alerts were monitored and responded to around the clock, and several wanted the 
possibility to choose for themselves whether a contact nurse should call them or not. Other 
components described as supportive by most of the patients were the self-care advice and 
the links to websites. The self-care advice was considered valuable, applicable, and 
informative. Reading the advice gave the patients an idea of what symptoms were normal 
and what they could expect during NACT. It also gave information on how to perform self-
care to relieve or manage symptoms, which allowed them to participate in their care. There 













7.6 Patients’ perceptions of care with or without using the 
Interaktor app (Study III) 
The thematic analysis of the patients perceptions of care during NACT and the role of the 
Interaktor app resulted in four overarching themes: “The healthcare context”, “Being a 




Figure 8. Illustration of themes and subthemes that emerged from the thematic analysis. 
 
The patients expressed the contact nurse as valuable and supportive during treatment and as 
the reason for patients perceiving continuity. When there was a lack of continuity the 
patients described not knowing who their contact nurse was or having to meet too many 
different healthcare professionals, which created feelings of confusion and insecurity. 
Perceived accessibility was described by the patients by knowing who to contact if they 
needed and that it was easy to get in touch with the healthcare professionals. Receiving 
enough time during visits or over the telephone was also expressed. Some patients 
described that they had not received contact information to the healthcare professionals or 
that it was hard to get in touch with the healthcare professionals because of occasionally 
switched off telephone or that the contact nurse returned the patients’ calls late or not at all. 
There were also patients who perceived not getting enough time during consultations with 
the healthcare professionals or having the opportunity to ask questions. 
The patients described the atmosphere at the oncology clinics in several positive terms such 
as friendly and warm. Moreover, they perceived having a dialogue with the healthcare 
professionals where both parts could ask and answer questions as well as have discussions. 
Patients expressed they felt trust, safety and were encouraged, as the healthcare 
professionals were interested in their wellbeing, listened to them, and treated them with 
respect and empathy. A few negative experiences leading to feelings of being one of a 
crowd were described by patients such as coldness and disinterest among the healthcare 
professionals, not being taken seriously or having to remind the healthcare professionals 
repeatedly regarding booking appointments with a physician or for treatments or 




received about the treatment and related symptoms, self-care, and planning, making them 
prepared for the treatment. However, sometimes the information was either perceived as 
too extensive, which was hard to take in, or insufficient, leaving unanswered questions. 
Patients described being active in searching for more information than they had been 
provided with by the healthcare professionals. Commonly the internet was used for that 
purpose. Moreover, patients described participating in their own care in different ways. The 
patients described being satisfied of being a passive receiver of care and trusted the 
healthcare professionals and accepted the treatment and planning since the highest priority 
was to get well. Patients who expressed having participated in their own care described this 
as performing self-care, being able to plan daily activities by having a treatment plan and 
discussing different matters regarding their care with the healthcare professionals. 
Occasionally participation in care was perceived by patients as difficult, especially since 
everything from diagnosis, treatment decision and planning to start of treatment happened 
so quickly. 
The patients who used the app perceived it as an easy and accessible source of information 
during treatment. Normal and expected symptoms caused by the treatment were explained 
in the app and the patients expressed being able to follow the self-care advice to manage 
symptoms instead of contacting the contact nurse. Further, the information and the links in 
the app were considered as a good complement to the information provided by the 
healthcare professionals. Using the app was also perceived as a safe, easy, and convenient 
way to get in contact with the contact nurse by being contacted directly in the event of 
severe symptoms. The patients stated that using app led to feelings of being seen and 
listened to. When reporting symptoms, the patients shared the information about their 
health condition with the contact nurse who monitored their reports and responded in case 
of severe symptoms. The patients described that using the app enabled them to take actions 
in their own care, such as performing self-care when symptoms occurred so as to feel 
better. By reporting symptoms, the patients described being active and being given the 
opportunity to daily reflect on their health. By being conscious and aware of symptoms and 
their patterns, self-planning was facilitated, and patients discovered that many days were 







8.1 Results discussion 
The main finding in this thesis is that the patients received additional support for managing 
symptoms and awareness of their own health by using the Interaktor app for supportive care 
during treatment with NACT. The patients used the app as intended and described it as easy 
to use, enabling access and interaction with the contact nurse and participation in their own 
care. 
8.1.1 Supportive cancer care by using Interaktor during neoadjuvant 
chemotherapy 
During the time of the RCT in this thesis all patients with breast cancer who underwent 
NACT received structured standard care at the clinics, including information about the 
treatment and routine follow-up by the contact nurse and physician. The patients were 
satisfied overall with the care they received during NACT, regardless of whether they had 
used the app or not. The patients described being supported by the contact nurse, who 
played an important role in providing them with information about the treatment and how 
symptoms should be managed, as well as being a person who they could contact when 
needed, according to the National Cancer Strategy for the Future (The Swedish 
Government Official Reports, 2009). Nevertheless, it emerged that using the app gave 
additional valuable supportive care during the treatment in several ways, which perhaps 
further reinforced the patients’ satisfaction with the care. This can explain why the patients 
in the intervention group rated a significantly lower prevalence in symptoms and symptom 
burden as well as showing significantly better emotional functioning in comparison to the 
control group two weeks after the end of NACT. Other studies of patients with prostate 
cancer during radiotherapy and patients with pancreatic cancer after surgery using 
Interaktor have shown similar results (Gustavell et al., 2020; Sundberg et al., 2017). It has 
previously been shown that emotional well-being can be supported by using mHealth 
(Dahlberg et al., 2018; Maguire et al., 2015). Symptoms in patients with lung cancer 
receiving radiotherapy were monitored while they were at home and they were either 
contacted or could contact the nurse by an app (Maguire et al., 2015). In the other study, 
patients were using an app for assessment of the quality of recovery after day surgery where 
they could request to be contacted by a nurse (Dahlberg et al., 2018). Moreover, it has been 
shown that patients with different cancer diagnoses had fewer visits to emergency 
departments, stayed on chemotherapy for a longer period and even increased survival 
(Basch et al., 2016; Denis et al., 2017). 
The most significant reduced symptoms and concerns in the RCT were feeling sad, nausea, 
vomiting, appetite loss and constipation, which are all common and related to 
chemotherapy and often perceived as distressing (Browall et al., 2017; Ward Sullivan et al., 
2017). The self-care advice for nausea was one of the most read pieces of advice and as 




management of this symptom (Dranitsaris et al., 2017; Navari & Aapro, 2016). Reduced 
symptoms for patients during treatment are beneficial not only for their well-being and 
quality of life, but also for the clinical care such as compliance with the chemotherapy 
regimen for longer, which can improve treatment outcomes (Bouchard et al., 2018; Davis et 
al., 2018). It has been described that a key aspect in supportive care for breast cancer during 
treatment is identification and management of symptoms (Zdenkowski et al., 2016). The 
Interaktor app enables daily reporting of symptoms as well as the opportunity for patients to 
reflect on their well-being, which renders early identification of symptoms from both the 
patients and the health care professionals. There were different opinions among the patients 
as to whether daily reporting was necessary, depending on how severely the symptoms 
were perceived. It is understandable that patients might think that it is more necessary to 
report symptoms when feeling unwell. Reflections over one’s own health are often made 
when feeling ill because the illness interferes with daily life (Ekberg, 2015). However, 
some patients stated the importance of highlighting days when they were feeling well, since 
this can become a positive reminder that there are days during the treatment which are 
trouble-free. Having the opportunity to visualize reported symptoms in graphs can enhance 
symptom awareness even more as the symptom patterns were visualized, which also 
facilitated the planning of activities. 
Irrespective of whether they were using the app or not, patients expressed that the 
information they received about the treatment and how symptoms should be managed was 
sometimes hard to digest, because of the overload of information that had been provided on 
only a few occasions. Furthermore, it is known that patients treated with chemotherapy 
have difficulties in concentrating and remembering, which may inhibit their necessary 
understanding of the treatment (Ibrahim et al., 2019; Myers, 2012). The patients described 
that Interaktor provided them with easy access to additional information and self-care 
advice, which enabled them to read the information whenever they needed. It has been 
emphasized that supportive care requires relevant and accessible information to meet the 
informational needs the patients might have whenever they have them Droog et al. (2014), 
Fiszer et al. (2014), and Loibl and Lederer (2014). 
The interviews revealed that the patients received support in performing self-care since the 
app gave them access to relevant advice for them to act on to obtain symptom relief. 
Moreover, it was comforting to be able to discuss self-care actions with their contact nurse. 
Digital solutions such as mHealth need to have an interactive function to facilitate 
communication between patients and healthcare professionals (Shaw et al., 2017) and 
having easy access to healthcare can provide timely supportive care (Hammer et al., 2019). 
Encouraging patients to perform self-care can attain symptom control and influence quality 
of life in a positive direction. However, it has been concluded that many patients with 
conditions such as cancer need support to perform self-care (Hoffman, 2013). The essence 
of self-care for patients with breast cancer is to understand the information on how to 




information provided in a dialogue with the healthcare professionals is imperative. This is 
especially important in outpatient-based care when there is less access to support from the 
healthcare professionals (Engqvist Boman et al., 2018). 
According to Swedish legislation, healthcare should as far as possible be designed and 
implemented in consultation with the patient. Further, if a patient participates by 
performing certain care and treatment actions, this must be based on the patient’s own 
wishes and individual conditions (The Swedish Riksdag, 2014). The findings in this thesis 
show that patients from the whole group were sometimes content to be passive receivers of 
care. Rather, patients described their wish to get well and that this was prioritized, so that 
they trusted and accepted everything that had been decided and planned regarding 
treatment. When patients talked about taking an active role, it concerned searching for 
information, performing self-care and having discussions with the healthcare professionals. 
Descriptions from the patients using the app revealed that using the self-care advice to take 
their own actions in symptom management enhanced participation in their own care. 
Participation can be enhanced even further when the actions in symptom management are 
taken in collaboration with the healthcare professionals (Howell et al., 2017). In the present 
RCT patients described feeling like an active participant when being contacted by a nurse 
in the event of severe symptoms, which were then discussed. This led to feelings of being 
safe, seen and listened to. These results are consistent with the findings in studies of other 
versions of Interaktor, as well as in studies evaluating similar interventions (Gustavell et al., 
2020; Göransson et al., 2018; Hälleberg-Nyman et al., 2017; Maguire et al., 2015; Weaver 
et al., 2014). According to Angel and Frederiksen (2015) participation must be based on the 
patients’ individual needs and it has to be made clear when patients have to participate, if it 
is possible and when patients can participate in their own care. This is a challenge since 
there must be a balance between safety and legal parameters versus the patients’ wishes, 
abilities and preferences to participate (Tobiano et al., 2015). For the patients who had used 
the app, it was obvious that using Interaktor allowed them to participate in their own care in 
different ways, which seems to have been supportive and improved the patients’ health and 
well-being. 
8.1.2 The importance of engagement in mHealth 
The adherence of reporting symptoms in the app as intended was high, which is comparable 
with results from patients with prostate cancer using Interaktor during radiotherapy and 
patients with pancreatic cancer after surgery (Langius-Eklöf, Christiansen, et al., 2017; 
Gustavell, Sundberg, et al., 2019). These are positive findings since high levels of 
adherence in using mHealth have been shown to be associated with improved outcomes 
(Donkin et al., 2011). High adherence has also been reported in patients with various cancer 
diagnoses using mHealth to support their needs related to cancer and treatment (Richards et 
al., 2018). In contrast to these results it has been shown that patients with chronic 
conditions such as diabetes, epilepsy, obesity, and mental health problems using web-based 




that social support and level of education influence the usage of web-based interventions, 
where high levels of social support and education are associated with an increase in 
engagement (Eysenbach, 2005; Perski et al., 2017; Ryan et al., 2018). In this thesis, a 
higher age of patients predicted a decrease in number of free text messages sent. However, 
it has been suggested by Rai et al. (2013) that demographic variables may be too broad to 
indicate usage motives for mHealth. To reach a high adherence an intervention needs to be 
meaningful and relevant to use in clinical care (Rose & Bezjak, 2009; Short et al., 2015). 
The notification sent out to remind the patients to report may have had a positive impact on 
adherence. Patients expressed the notification as being helpful in reminding them to report 
in the app. It is also important that the interventions are co-created with patients and 
healthcare professionals (Rose & Bezjak, 2009). By doing this, valuable experiences and 
needs are highlighted, and interventions can be developed to better suit the patient and 
improve engagement in the intervention (Boyd et al., 2012). During the development phase 
for the version of Interaktor in this thesis, the app was pilot tested during which both 
patients and healthcare professionals shared their suggestions to optimize the app. 
All patients who were randomly selected to use Interaktor were given instructions and 
practiced reporting in the app on one supervised occasion. This is a strength and reflects the 
user friendliness of Interaktor. It has been argued that when implementing new systems 
such as mHealth, it is essential that the patients are provided with supervised training on 
several occasions to be comfortable in using them (Seto et al., 2012). However, in this 
RCT, the introduction of Interaktor seems to have been sufficient, considering the regular 
reporting and frequent use of the different components of the app as described previously 
and below. 
Most of the patients who used Interaktor said it had been easy and convenient and was 
considered as an accessible source of information with negligible technical problems. This 
is emphasized by Dennison et al. (2013) showing that by using mHealth, the support 
becomes more accessible compared to computer-based systems since the patients can easily 
carry smartphones or tablets with them. It is estimated that around 90% of households in 
Sweden have access to a smartphone (The Swedish Internet Foundation, 2019). In the 
present RCT, only two patients needed to borrow a smartphone because they did not own 
such a device. Furthermore, all components in the app had been applied with a high, 
although, individual degree of usage. All symptoms included in the app were reported at 
some time and all self-care advice were viewed at least once by all patients. Only a few 
patients perceived the reminder as negative, where they felt that being required to report 
during days when they were feeling well could be a negative reminder of their illness. 
Despite this, most patients preferred to report their symptoms during days when they felt ill 
even though it occasionally was stressful. But since the app was perceived as easy to use 
and reporting was quick, this was not a major issue. 
When an alert was triggered, the patients were called by a contact nurse. Most of the 




perceived it as unnecessary and wanted to choose for themselves whether to be contacted or 
not, especially if the same symptom occurred over several days. When Interaktor was tested 
in patients with pancreatic cancer, two approaches were tried regarding who should be 
responsible for initiating the contact (Gustavell et al., 2018). The first one was the same 
approach as in this RCT. In the other approach, after submitting a report, the patients could 
choose if they wanted to be contacted by a contact nurse. Results revealed that opinions 
about the approaches differed between the patients and it was concluded that since patients 
with pancreatic cancer have a poor prognosis and often perceive severe symptoms, the 
responsibility to contact the healthcare professionals should not be put on the patients. 
Results from another study show that patients with different cancer diagnoses may find it 
hard to estimate when their symptoms are considered to be serious and thereby needing 
contact with the healthcare professionals (Jansen et al., 2015). Considering these findings, it 
was concluded by Gustavell et al. (2018) that alerts should continue to be triggered and 
responded to by a nurse. In the app, the patients can send a free text message if they do not 
wish to be contacted by a contact nurse. In the future development of Interaktor, a more 
convenient way to communicate the need to be contacted and why, could be integrated into 
the risk assessment model. This may also prevent the patients from adjusting their reports 
by reporting lower frequency and distress levels of symptoms in order to avoid being 
contacted by a contact nurse. 
There were some suggestions for improvement given by the patients. Some patients 
proposed to add additional symptoms, such as headaches and that the symptom pain should 
be divided into several categories depending on the cause, such as pain in the breast caused 
by the remaining tumor and pain in muscles and joints caused by the chemotherapy. Also, 
there were suggestions to extend the self-care advice about diet and psychological 
symptoms. However, when adding symptoms for assessment there must be a balance 
between relevant symptoms to report and the time it takes to report. The component with 
the free text function gave the patients the opportunity to report additional symptoms or 
concerns that were not assessed, which could address the lack of individually-related 
symptoms or concerns. In the future, it will be important to develop the app to be even 
more individualized for example to enable them to add or exclude symptoms and self-care 
advice according to their specific needs (Moradian et al., 2018). Updating information 
regularly according to each patient’s progress during the treatment trajectory can also be a 
way to meet individual needs even more and maintain personal relevance (Short et al., 
2015). 
 
8.2 Methodological discussion 
8.2.1 Design  
This thesis represents phase III underpinned by the MRC framework (Craig et al., 2013; 




qualitative approaches were used, which is considered as a strength as it gives knowledge 
and insights of an intervention from several angles. Using a qualitative approach is useful 
as a complement to the quantitative approach, to gain a deeper understanding of why the 
intervention is supportive for the patients (Medical Research Council, 2000) not least when 
evaluating the use of mHealth apps (de Korte et al., 2018; Vo et al., 2019). 
8.2.2 Setting and sample 
The RCT was conducted in an outpatient setting and involved women with breast cancer 
treated according to structured national care guidelines. The results in this thesis may limit 
the generalizability of the results to all other groups of patients with breast cancer. 
However, Interaktor can be adapted to other samples and settings and has been shown to be 
acceptable, feasible and clinically significant in men with prostate cancer, women and men 
with pancreatic cancer and in older persons receiving home based care (Algilani et al., 
2017; Gustavell, Langius-Eklöf, et al., 2019; Göransson et al., 2018; Langius-Eklöf, 
Christiansen, et al., 2017). 
To include a sufficient number of patients in the RCT, a sample size calculation was 
conducted to estimate the sample size for Study I. As there was no data available from the 
current population, the sample size was calculated from the results of a study on patients 
with prostate cancer (Sundberg et al., 2017), which may have an impact on the results. 
However, as the power was calculated on the primary endpoint symptom burden and on 
patients with cancer it was considered as relevant for the sample size calculation in this 
RCT. 
The inclusion criteria for the RCT were broad with the intention to include all patients 
planned for NACT. For pragmatic and safety reasons, patients had to be able to read and 
understand Swedish and be cognitive able to participate. In total, 47 eligible patients 
declined to participate in the RCT. Even though they were not asked the reason for 
declining, the patients spontaneously expressed that the main reasons were lack of energy 
or interest or that they were already participants in other studies. At baseline, the 
intervention group and control group did not significantly differ in sociodemographic- 
and/or clinical data, which shows that randomization worked properly. Dropout rate during 
the study was considered to be low and was similar in both groups which could reflect an 
opinion among the patients that it was a relevant study and their interest to contribute to 
nursing research. 
8.2.3 Questionnaires 
Two questionnaires were used to evaluate whether the app had impact on patients’ 
symptoms and health-related quality of life. The questionnaires MSAS and EORTC QLQ-
C30 are both well validated and reliable questionnaires developed for patients with cancer 
(Aronson et al., 1993; Browall, et al., 2013). The internal consistency was very good 
overall except for the symptom scale nausea/vomiting in EORTC QLQ-C30. Similar results 




other studies with non-malignant pain (Fredheim et al., 2007) and in general populations 
using EORTC QLQ-C30 (Derogar et al., 2012; Michelson et al., 2000). It is common that 
scales with few items have small alphas (Field, 2017). 
The RCT showed relatively small effects in the symptom subscales and in the emotional 
functional scale of the EORTC QLQ-C30, although some of the symptom scales almost 
reached medium effects. Interpretations of the EORTC QLQ-C30 scales have suggested 
that a mean change of >10% in the scores within the groups is considered as clinically 
meaningful and classifies the patients’ scores into improved, stable or worsened (Osoba et 
al., 1998; Osoba et al., 2005). Using this method to interpret the scores in this RCT revealed 
improved, stable and worsened scores in the functional and symptom scales for both 
groups. This may help when deciding appropriate supportive care for the patients and can 
therefore be clinically relevant even if the results showed small effects. 
It can be discussed why two such comprehensive questionnaires were used. First, 
symptoms and symptom burden were assessed with the MSAS. Since it is known that 
symptoms directly influence quality of life (Browall et al., 2013) the EORTC QLQ-C30 
was also used. This questionnaire is suitable to assess health-related quality of life in 
populations with cancer (Aronson et al., 1993). Also, the MSAS questionnaire is 
appropriate for use in both clinical assessment of patients’ symptoms and in research 
(Browall et al., 2013). In the RCT, the MSAS was used both as questionnaires which the 
patients responded to and as an inspiration when developing the symptom reporting 
questions in the app, where prevalence, frequency and distress levels were assessed. 
Moreover, MSAS was considered as appropriate and relevant to use in the patients included 
in this RCT since it includes symptoms commonly perceived during chemotherapy. 
Assessing symptoms from several dimensions, where the patient’s individual perceptions of 
the symptoms are in focus, is also the concept behind using PROs (Basch et al., 2016; Chen 
et al., 2013). It was discussed whether to use other questionnaires for assessing symptoms 
and health-related quality of life, such as FACT-B and EORTC QLQ-BR23. However, they 
include items concerning symptoms perceived after surgery and during antihormonal 
treatment, which were not relevant considering the context in which Interaktor was used in 
this RCT (Nguyen et al., 2015). In this thesis, it was chosen to report only the ratings of 
prevalence of the symptoms and the subscales in the MSAS. In clinical care, when the 
contact nurse needs to assess and communicate a patient’s symptoms, it is recommended to 
use all three dimensions of frequency, severity and distress to gain a detailed picture of the 
patient’s symptom profile (Pettersson et al., 2014). 
Analysis of covariance was performed adjusting for baseline values. By adjusting for 
baseline covariates, the precision of the outcomes improves (Steingrimsson et al., 2017). 
Results in the thesis showed significant differences between the intervention group and the 
control group in symptoms and health-related quality of life. There is always a risk that the 
results are due to chance rather than a factual difference. The risk of drawing inaccurate 




significance level had been set to 0.01 (1%) instead of 0.05 (5%), the risk of drawing 
conclusions that a difference exists when there is no actual difference is reduced even more, 
however differences calculated with a t-test are harder to detect (Field, 2017). Reporting 
statistical significance only describes whether there are differences between two groups. 
Therefore, in Study I effect size was calculated, which is important to gain even further 
information of how much the intervention affects the patients (Sullivan & Feinn, 2012). 
In studies there is always a risk of missing data. No questionnaires were missing at 
baseline, however, after end of NACT, five complete questionnaires were missing in the 
intervention group and four in the control group. A strength in the statistical analysis was to 
use a modified intention-to-treat analysis approach to handle the missing data. To replace 
missing data, BOCF was used as imputation method. This method was chosen since it is 
suitable when patients drop out after baseline assessment, as well as when there are low 
levels of missing data, mainly because this is a well-known conservative method and there 
is a risk of either under- or overestimating the results (Liu-Seifert et al., 2010; Petroff, 
2017; Shao et al., 2009). Therefore, a complete case analysis was also performed. Analyses 
using both methods revealed similar results, which is a strength of the study results. The 
overall dropout rate in the RCT was considered as low (6%) and the personal relevance and 
contribution to research expressed by the patients may have played an important role in 
motivating them to participate in the study. Also, if the questionnaires were not responded 
to by the patients’ they were reminded by researcher up to three times. This procedure was 
however very rare. 
8.2.4 Logged app data 
Analyses and assessment of logged data within mHealth interventions are important to get 
insights into the patients’ usage behavior throughout an intervention (Eysenbach, 2005). It 
is not only important to assess when and how often the patients use the app it is also vital to 
assess how the patients use the app, to gaining further knowledge of the effectiveness of 
mHealth (Stragier et al., 2019). In the RCT, the patients’ app usage was logged except 
clicked links and viewed graphs, which may be a limitation to gain an overall picture of 
how Interaktor was used and is something that will be taken under consideration in 
forthcoming studies of Interaktor. However, conclusions of how the links and graphs were 
used can be made from the interviews conducted with the patients after the reporting period 
had ended. 
8.2.5 Interviews 
To establish trustworthiness in the qualitative approach in this thesis, the criteria credibility, 
confirmability, dependability, and transferability according to Lincoln and Guba (1985) 
were considered. Credibility in qualitative data refers to the truth in the data, analysis, and 
interpretation of the results and since the researcher is the instrument in the analysis, it is 
important to know the researcher’s knowledge and preunderstanding (Polit & Beck, 2016). 




interviews and related transcriptions, had both theoretical knowledge and practical 
experience of working with patients with breast cancer during NACT. The analyses in 
Studies II and III, were made with an inductive approach and therefore, it was important to 
be aware of the pre-understanding as this may affect the analysis and reported results. To 
increase credibility, analyses were conducted in transparency with the other researchers, by 
continuously reviewing and discussing the analysis with each other to come to consensus 
and to ensure that the categories and themes covered the data and responded to the study 
aims. 
In Study II, telephone interviews with the patients who had used the app were conducted 
shortly after the patients’ final report to ensure the patients remembered the use of the app 
as much as possible. A potential weakness is that the interviews were not audio recorded 
and analysis was made from the notes taken during the interviews. This may affect 
confirmability of the findings, which means accuracy of data and that the findings are in 
line with what the patients said (Polit & Beck, 2016). However, the interview guide was 
developed so that the questions generated short answers but still captured the usability and 
utility of the app and were easy to write down in the template of the interview guide. Also, 
the researcher who conducted all interviews wrote down the patients’ statements with 
accuracy to capture as much as possible of the patients’ own words in the statements. Data 
from the analyses revealed richness in the material sufficient to get a deeper understanding 
of how the patients used the app. 
In Study III, all face-to-face interviews were conducted in a secluded room at the oncology 
clinics according to the patients’ wishes. Often the patients had various visits planned at the 
clinics relating to their illness and treatment, so the interviews were planned to be 
conducted in connection with these visits for reasons of convenience. Also, given that the 
interviews were conducted over a period of one and a half year, this was something that 
may positively affect dependability, which means the stability of findings over time 
indicating the care and treatment were performed in a similar way. However, in the last 
interviews it was noted that no new information was added, which indicates saturation of 
data (Polit & Beck, 2016). To establish dependability further, most interviews were 
conducted by the researcher of this thesis who followed a semi-structured interview guide, 
which, as far as possible, ensured that the interviews were conducted in a similar way. A 
weakness in Study III is that the interviews were conducted three months after end of 
NACT, which may have led to difficulties for the patients to remember how the treatment 
period was perceived with or without the use of Interaktor. However, the data from the 
interviews testified that the patients remembered the period well and were able to deliver 
rich descriptions of how they perceived the care and use of Interaktor. 
In Study II, conventional content analysis according to Hsieh and Shannon (2005) was 
chosen to analyze the telephone interviews. The method was chosen since it is suitable for 
describing a phenomenon where limited knowledge exists (Hsieh and Shannon, 2005), 




patients perceived using Interaktor. In Study III, thematic analysis according to Braun and 
Clarke (2006) was chosen to analyze the face-to-face interviews. This method is considered 
as a flexible method when interpreting the data. Also, it is recommended for investigating 
patients views and experiences as well as for large sets of data that can be approached by 
sorting them into broad themes, which was the case in Study III (Braun & Clarke, 2006; 
Nowell et al., 2017). 
Transferability is described as the counterpart of the term generalizability in quantitative 
research and refers to the extent the results can be transferred to other samples and settings 
than the ones studied (Polit & Beck, 2016). The interviews in Study II and III both 
included large samples with a wide range of sociodemographic and clinical characteristics 
of the patients and the descriptions from the patients were considered as rich. These aspects 








The findings in this thesis show that patients with breast cancer undergoing NACT receive 
individual supportive care by using an interactive app such as Interaktor. Reduced 
symptoms and increased emotional functioning were achieved through provision of 
information and self-care advice, the monitoring of symptoms and easy access to healthcare 
professionals. 
Patients were highly engaged in using the app and it enabled them to share knowledge and 
discuss their health with the contact nurse as well as taking their own actions to better cope 
with the treatment. Enhanced communication and interaction with a contact nurse promoted 
patients to participate in their own care. 
Overall, both study groups stated they had been satisfied with the care during treatment, 
reflecting a well-organized healthcare. Notwithstanding, using an interactive app provided 





















10 CLINICAL IMPLICATIONS 
This thesis provides increased knowledge that patients with breast cancer can be supported 
by using an interactive app during NACT to support self-care between treatments. 
Reporting symptoms regularly to the healthcare professionals enables them to identify the 
patients’ distressing symptoms early so they can be discussed with the patients and thereby 
timely and supportive care can be provided. This is important as symptom relief will very 
possibly lead to increased wellbeing and quality of life, as well as a better understanding of 
how to take part in their own care. Further, enabling patients to monitor their reported 
symptoms over time and reflections over their health can facilitate planning of activities 
based on how they usually feel between the treatments. 
Patients with breast cancer will most likely continue to receive their care and treatment on 
an outpatient basis in the future and mHealth can provide supportive care for those patients 
as well as address the different needs the patients have, and through that support more 
person-centered healthcare. 
To implement technology such as mHealth, its value as additional supportive care for the 
patients must be highlighted and widely spread to patient organizations, clinicians, 
stakeholders, and politicians. An implementation process must be carefully planned and 
conducted by involving all concerned parties responsible for the care for patients with 
breast cancer. 
The findings in this thesis also provides knowledge that might facilitate collection of PROs 
















11 FUTURE RESEARCH 
The next step to take with the breast cancer version Interaktor would be phase IV (Long 
term implementation) according to the MRC framework to integrate the use of Interaktor 
into clinical practice, where a goal is that all patients should be offered to use the app 
during their treatment and then identifying those who are interested to do so. As part of this 
phase, co-creation with the clinical settings should be conducted to investigate how the 
nurses perceive working with innovations such as mHealth to support patients and how 
nursing interventions such as Interaktor can facilitate their work to provide the right 
supportive care to the right patients at the right time. Also, a health economic evaluation of 
the app and its use needs to be conducted to provide information regarding the economic 
outcomes when using the app. 
It would also be interesting to further study the use and value of Interaktor during the 
follow-up phase of patients with breast cancer. It is known that patients perceive lack of 
support and often feel abandoned and outside of the healthcare in the aftermath of the long 
treatment period. It is during this phase late effects and symptoms of chemotherapy and 
radiation therapy occurs. Also, it is common today that patients undergoing antihormonal 
treatment during ten years after chemotherapy, surgery, and radiation therapy. This 
treatment often causes symptoms, and the patients are followed-up once a year for 
symptom control, mammography, and prescription renewal of antihormonal drugs. There is 
therefore reason to believe that an app like Interaktor can be a complement during this 
follow-up by early identifying symptoms and providing self-care to prevent the patients 
















12 SVENSK SAMMANFATTNING (SUMMARY IN SWEDISH) 
 
Bakgrund 
Patienter med bröstcancer som genomgår neoadjuvant cytostatikabehandling upplever ofta 
flertalet besvärande symtom som kan påverka deras livskvalitet negativt under en lång tid. 
De flesta patienter får sin vård och behandling i öppenvård vilket innebär att symtom 
orsakade av sjukdom och behandling måste hanteras av patienterna hemma. Om symtom 
inte hanteras i tid finns förutom risk för sämre livskvalitet även risk för att behandlingen 
måste skjutas upp eller i värsta fall avbrytas, vilket kan resultera i sämre 
behandlingsresultat. Många patienter upplever att de saknar tillräcklig information och stöd 
för att hantera sina symtom under behandlingen. För att möta detta behöver såväl symtom 
som patienternas behov av stöd identifieras, utvärderas och hanteras. Ett sätt att göra det är 
genom mHälsa till exempel smartphones, då rapportering av symtom via digital teknik har 
visat sig kunna öka interaktion och kommunikation med vården samt minska symtom och 
förbättra livskvalitet hos patienter med cancer. 
Syfte  
Det övergripande syftet med denna avhandling är att utvärdera hur en interaktiv app för 
rapportering och hantering av symtom kan ge stödjande vård till patienter med bröstcancer 
under neoadjuvant cytostatikabehandling. 
Appen Interaktor 
Fokus för appen är patientperspektivet genom att stötta med information, egenvårdsråd och 
öka tillgängligheten till vården och därmed främja patientens delaktighet i sin egen vård. 
Innehållet i appen är utvecklat utifrån litteratur av aktuell forskning inom området, rutiner 
och riktlinjer samt intervjuer och diskussioner med patienter och personal på klinikerna. 
Appen är interaktiv där patienten gör dagliga skattningar av förekomst, frekvens och 
besvärsgrad av symtom som är vanligt förekommande under neoadjuvant 
cytostatikabehandling. Patientens rapportering överförs via en säker server till ett 
webbgränssnitt där en kontaktsjuksköterska kan se vilka symtom som patienten har 
rapporterat samt även läsa fritextmeddelanden från patienten. Om patienten rapporterar 
symtom av svårare grad, går ett larm till kontaktsjuksköterskan som sedan ringer upp 
patienten för att ge stöd eller råd. I appen har patienten också tillgång till egenvårdsråd och 
internetlänkar för ytterligare information om hur symtom kan hanteras. Patienten kan också 
via grafer se sina rapporterade symtom. 
Metod 
Utvecklingen och utvärdering av appen följer ett ramverk för komplexa interventioner. 
Denna avhandling innefattar fas III i ramverket, vilket är en randomiserad och kontrollerad 




kvantitativ som kvalitativ ansats. I Studie I ingår 149 patienter som randomiserades till en 
interventionsgrupp (n = 74) och en kontrollgrupp (n = 75). Patienterna i 
interventionsgruppen rapporterade sina symtom i appen under den neoadjuvanta 
behandlingstiden i kombination med sedvanlig vård. Patienterna i kontrollgruppen erhöll 
endast sedvanlig vård. Båda grupperna fyllde i enkäter avseende symtom och livskvalitet 
före start av behandling och två veckor efter avslutad behandling som sedan analyserades 
sedan för att utvärdera och jämföra interventionens effekter på patienternas skattade 
symtom och hälsorelaterad livskvalitet. I Studie II undersöktes patienternas 
användningsmönster av appen under behandlingstiden. Studien omfattar samtliga patienter 
som använde appen (n = 74). Loggade data från användningen av appen analyserades samt 
om det fanns faktorer som påverkade användningen. Telefonintervjuer gjordes med 
patienterna efter avslutad rapportering för att undersöka deras upplevelse av att använda 
appen. I Studie III intervjuades patienter från båda grupperna (n = 40) tre månader efter 
avslutad behandling avseende deras upplevelser av vården under behandlingstiden med 
eller utan stöd av appen. 
Resultat 
Resultaten i Studie I visade att patienterna som använde appen under behandlingstiden 
upplevde färre symtom såsom illamående, kräkningar, aptitlöshet, förstoppning och 
nedstämdhet samt hade mindre oroskänslor, irritation och nedstämdhet två veckor efter 
avslutad behandling jämfört med de patienter som inte använt appen. I Studie II visade 
resultaten att patienternas följsamhet att rapportera sina symtom som planerat var 83%. De 
vanligaste symtomen som rapporterades i appen var trötthet, munproblem och 
sömnsvårigheter. Fritextfunktionen användes av majoriteten av patienterna. Samtliga 
patienter läste egenvårdsråden i appen där munproblem, illamående och smärta var de 
vanligaste lästa råden. Den enda faktorn som påverkade användningen av appen var att ju 
högre ålder patienterna hade desto färre antal fritextmeddelanden skickades. Patienterna 
upplevde appen som lättanvänd med relevant innehåll och de flesta ansåg att daglig 
rapportering var som mest betydelsefullt de dagar de mådde dåligt. Egenvårdsråden ansågs 
värdefulla och lättillgängliga för att stötta patienterna i att utföra egenvård av upplevda 
symtom. Graferna möjliggjorde egen monitorering av symtom som underlättade för 
planering av dagliga aktiviteter. Att rapportera och använda appens olika funktioner 
beskrevs av patienterna som att få möjlighet att reflektera över sin egen hälsa, ha en nära, 
kontinuerlig och interaktiv kontakt med kontaktsjuksköterskan vilket upplevdes som tryggt, 
att bli sedd och vara delaktig i sin egen vård. Resultaten i Studie III visade att patienterna 
överlag var nöjda med vården som de fått under den neoadjuvanta cytostatikabehandlingen, 
oavsett om de använt appen eller inte. Patienterna beskrev ibland brist på kontinuitet som 
innebar att de träffade olika vårdpersonal under sin behandlingstid eller att de inte visste 
vem deras kontaktsjuksköterska var. Patienterna upplevde också tillfällen med svårigheter 
att nå vårdpersonalen när de behövde. Att vara delaktig i sin egen vård upplevdes i 
varierande grad beroende på vilket behov de hade. De patienter som använde appen beskrev 




som en lättillgänglig källa för information om behandling och egenvård och erbjöd ett lätt 
sätt att komma i kontakt med vården vid svårare symtom. Patienterna upplevde även att 
appen möjliggjorde kommunikation och delaktighet i vården genom att rapportera symtom 
och utföra egenvård för att må bättre 
Slutsatser  
Patienter med bröstcancer kan under pågående neoadjuvant cytostatikabehandling få stöd 
utifrån individuella behov genom att använda en interaktiv app som Interaktor. Interaktion 
och kommunikation mellan patient och kontaktsjuksköterska underlättas genom att 
patienten rapporterar symtom i hemmet och blir kontaktad av en kontaktsjuksköterska på 
kliniken vid svårare symtom. Patienten får möjlighet att reflektera över sin egen hälsa, har 
enkel tillgång till information och egenvårdsråd samt har möjlighet att följa sin 
symtomrapportering via grafer. Detta gör att symtom kan identifieras och hanteras tidigt 
vilket kan leda till att patienten upplever symtomminskning och förbättrad livskvalitet samt 
känner sig trygg, sedd, omhändertagen och delaktig i sin egen vård. Även om patienterna i 
studien uppgav att de var nöjda med vården som de hade fått under behandlingstiden, 
beskrevs användandet av appen ge ett mervärde och utgjorde ett lättillgängligt, relevant och 
värdefullt stöd under behandlingen. Avhandlingens resultat visar att det är högst motiverat 
att rekommendera användning av en interaktiv app under cytostatikabehandling för 
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